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It has been well recognized that biologics are efficient for cancer and immune 
disease treatment. Kinetic modeling is to mathematically model or to quantitatively 
illustrate how reactions occur in a biological or chemical process. A systematic study 
and understanding of kinetic model and its application in the biopharmaceutical 
industry are important for both scientific research and industrial technology 
development.  
This work consists of six chapters. First, a review of kinetic modeling and its 
application for cell culture was introduced. Second, the current status of biologics 
development and screening strategies of biomarkers and indications were discussed. 
Third, one experimental and kinetic modeling study for the temperature effects and 
temperature shift strategy development was presented. Forth, novel kinetic models were 
built up and applied to elucidate lactate dehydrogenase catalyzed reactions, which is a 
crucial metabolic process within tumor cells and Chinese hamster ovary cells. In the 
fifth chapter, strategies of biologics quality control via process development were 
briefly summarized. And finally, summary and outlook were made based on the above 
five chapters. 
Though kinetic modeling is not a FDA request tool, kinetic data are required for 
regulation approval of new drug discovery and process development. These data are 
applicable for a rapidly screening of the best biologics and the optimized manufacturing 
process with little extra cost via kinetic modeling. This work is potentially beneficial 
for speeding up and better understanding of the current biologics development in 
biopharmaceutical industry. 
 
Key Words: Chinese Hamster Ovary (CHO) cell, cell culture, kinetic modeling, 
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Biologics is applicable in treating cancer and immune system diseases. From the 
first mAb OKT3 approved by FDA in 1986 to the recent approved chimeric antigen 
receptor T-cell immunotherapy (CAR-T) on August 30PthP 2017, the biopharmaceutical 
industry has been expanding at an ever faster pace in the recent three decades. To get 
approved for commercial use, complex pre-clinical development and clinical studies 
are needed to ensure the safety, stability, and efficacy of the biologics, which typically 
lasts 10 to 12 years. Thus, efficient methods to illustrate the biologics production 
process, enzyme and cell properties, are helpful for biologics discovery and 
development, as well as for potentially accelerating the commercialization process. 
Biologics screening and process developments are two major tasks in the pre-
clinical stage. Current strategies are mainly based on two sets of criteria:  
A) Static parameters evaluation. For example, peak VCD, final titer, final quality 
profile are frequently used for process development.  
B) Thermodynamic parameter evaluation. For example, binding affinity is 
typically used for antibody-dependent cell-mediated cytotoxicity evaluation to 
screening the best performance biologics.  
However, little process information can be directly reflected from the above two 
strategies, without which the process development and biologics screening would be 
heavily experience dependent as well as risky in missing the best options. Herein 
additional kinetic modeling is serving as a tool to make up these drawbacks. Kinetic 
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modeling is dependent on the understanding of the enzymatic mechanism within cells, 
which can promote new drug discovery, guide clinical study, efficacy explanation, and 
enhance cell metabolism understanding. 
In this dissertation, an attempt on the systematic study of kinetic modeling and its 
application to biologic screening, process development and enzymatic mechanism 
understanding were made. It aimed at benefiting the biopharmaceutical industry to 






Kinetic Modeling of CHO Cell Culture: principle and Application 
1.1. Abstract 
As a host for therapeutic proteins, Chinese Hamster Ovary cell is widely utilized 
in the mainstream biopharmaceutical industry. Cell culture process development 
plays an important role stepping from lab research to manufacturing. Among 
different mathematic tools, kinetic modeling is commonly achieved through 
analyzing cell culture data to design process parameters, optimize medium, and 
scale up the reactors. In this review, we examined key factors for upstream process 
development, and summarized currently used kinetic modeling strategies. 
Meanwhile, one original example of kinetic modeling application in optimizing cell 
culture performance is presented. This review aims at providing a comprehensive 
understanding of kinetic modeling and its application for cell culture process 
development.  
 
Keywords: Chinese hamster ovary (CHO), kinetic modeling, cell culture, therapeutic 
protein 
 
Abbreviations: CHO, Chinese hamster ovary; dhfr, dihydrofolate reductase; FDA, 
Food and Drug Administration; GS, glutamine synthetase; mAb, monoclonal antibody; 
M-M, Michaelis-Menten; MSX, methione sulphoximine; MWC, Monod-Wyman-
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Changeux; VCD, viable cell density; 
1.2. Introduction 
Chinese Hamster Ovary (CHO) cells, as one type of mammalian cells, were first 
introduced in 1957 by Theodore T. Puck when fibroblast cells were recovered from the 
cultured ovarian cells of a partially inbred Chinese hamster [1]. CHO cells have since 
become the preferred host for therapeutic protein production. Since the first biologics 
gained approval in 1986 [2], Around 75 monoclonal antibodies (mAbs) and fusion 
protein products have been approved in the US or Europe with about 70 % of them 
produced by CHO cells as of July 2017 [3-6]. The total sales of these top 10 biologics 
valued at $ 61.2 billion [5], while 500 antibody-based biologics were in the clinical 
stage in 2016 [6].  
As one bridge connecting lab research to manufacturing, cell culture process 
development is an important step to  biologics commercialization [7]. Significant 
progresses in CHO cell line engineering, media development, and process control, have 
enabled cell culture to achieve the titers of 3-6 g/L, which is now common for typical 
industrial fed-batch cell culture [8-10]. However, many challenges still remain in this 
field. First, higher titer will likely become necessary given the limited manufacturing 
capacity and high demands for multiple products. Second, the proteins produced need 
to have consistently specific product quality attributes for safety and efficacy. Finally, 
cell culture processes need to be robust and scalable from the lab to manufacturing 




While the current practice of cell culture process development is heavily empirical 
and may result to inefficiency in some cases, kinetic modeling performs as a 
mathematic tool to efficiently evaluate, analysis and optimize cell culture processes.[12] 
With structured or unstructured kinetic models, cell culture performance can be 
quantitatively evaluated and predicted. Meanwhile, it allows multiple process 
variations to be optimized simultaneously. This leads to fast critical process parameter 
evaluation and accelerates process development speed, which potentially benefits the 
automation system set-up in cell culture, reduces the lab work load and saves time and 
resources [13]. 
In this chapter, we summarized critical cell culture factors, and reviewed current 
cell culture kinetic modeling strategies. One kinetic modeling case study on medium 
optimization was shown, followed by a discussion of the current challenges and 
perspectives. This work aims at providing a comprehensive understanding of the cell 
culture kinetic modeling principle and application. 
1.3. Overview of CHO cell culture upstream factors 
The performance of CHO cell culture are determined by multiple factors working 
in synergy: cell line, cell culture media, process parameters and bioreactor modes, etc. 
are the critical ones that impact on the titer and protein quality. Each of them will be 
discussed in this section. 
1.3.1. Cell lines 
The first step of recombinant protein expression in mammalian cells is the 
6 
 
transfection of the product transgene to the host cells. Subsequently, hundreds to 
thousands of individual clones are screened to obtain a few clones with the desired 
characteristics such as good growth rate, high protein titer and qualified quality 
attributes. In order to significantly reduce the number of undesired clones, stringent 
selection pressure is necessary. Fig. 1-1 presented the commercial CHO cell line 
pedigree since the original cell line in 1957 [14-19]. It indicates that modern cell line 
development employs either dihydrofolate reductase (dhfr) or glutamine synthetase 
(GS) gene as a basis for clone selection. 
Different clones coming out from the same clone screening process can have 
various performance, even when they are cultured using the same process. Some of the 
phenotypic differences have been shown to be due to the intrinsic gene expression of 
the cells [20]. Better understanding of gene-trait relationship will be warranted for more 
































Fig. 1-1. Commercial CHO cell line pedigree. 
 
1.3.2. Medium 
An optimized medium provides balanced nutrients to sustain the cell growth and 
high protein titer expression, while simultaneously reduces accumulation of toxic 
metabolic byproducts [21, 22]. The first generation of media used in the industry 
contained serum and/or other undefined components such as hydrolysates to boost cell 
growth and productivity. However, serum containing media posed potential risks for 
viral contamination. In addition, it was recognized that lot-to-lot variation of those 
undefined components can result in inconsistent process performance such as cell 
growth, titer and product quality [23, 24]. The modern cell culture media contain fully 
chemically defined components for high process consistency and robustness. This type 
of media allows a mechanistic understanding of each component, pertinent 
improvement of productivity and control of the protein quality attributes based on the 
cell metabolism [25, 26], and in turn kinetic modeling can assist the optimization of 
medium composition for specified goals. 
A well-developed chemically defined medium may roughly contain tens to a 
hundred components according to the purpose it is used. It typically includes 
carbohydrates, amino acids, growth factors, lipids, polyamines, trace elements, and 
vitamins [27, 28]. With the advent of fully chemically defined media, it is now, in theory, 
possible to explore the impact of each individual medium components on the cell 
culture performance. The future media development will likely be tailored specific to 




Typically, glucose is the main carbon and energy source for mammalian cell culture, 
meanwhile other carbohydrates such as mannose and galactose may be used as auxiliary 
sources which has an impact on product quality [22]. A number of amino acids in 
chemically defined media serve as the main nitrogen source and secondary energy 
source. In addition to essential amino acids, selected non-essential amino acids are 
included in chemically defined media depending on the specific cell line and product 
requirements [9]. 
Mammalian cells convert these glucose and amino acids into energy, in the form 
of ATP, and other cellular building blocks through the central metabolic pathways (Fig 
1-2). In these pathways, glucose is first converted to pyruvate, which can then either 
enters the tricarboxylic acid (TCA) cycle for complete oxidation or be channeled 
toward lactate production. Glutamine and glutamate enters the TCA cycle through the 
glutaminolysis pathway, while releasing the ammonium groups [29]. Thus, glutamine 
and glutamate and glucose are the typical three major components that are traced during 





Fig. 1-2. General metabolic processes within CHO cells [30, 31]. The kinetic modeling 
principles of selected key pathways are shown in Table 1-3. 
 
1.3.3. Bioreactor Modes 
Cell culture is conducted in bioreactors which can be operated either in  batch, 
fed-batch or perfusion mode. Batch culture, with no feed being added to the culture, 
[32] is usually used to obtain information on cell growth and cell stability at the lab 
scale. Its further application for commercial manufacturing is limited due to the 
eventual nutrient depletion and the toxic metabolites accumulation.  
Fed-batch culture is currently the most prevalent mode for commercial 
manufacturing. A feed solution containing concentrated nutrients are supplemented to 
the production culture. This additional nutrients supply can sustain cell growth to higher 
cell density and maintain production of the recombinant protein for longer duration [33]. 
A typical fed-batch CHO cell culture can last about two weeks. 
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Perfusion culture has recently garnered a renewed interest in the industry. In this 
mode, fresh media replete of nutrients continuously flows into the reactor while 
perfusate containing the toxic metabolites, product and cells are continuously removed 
from the reactor at steady state [34]. Thus, the cells remain healthy and the process can 
be operated continuously. It has reported that the cell culture can last for up to six 
months [35]. Perfusion culture is particularly preferred for unstable products, such as 
Factor VIII, which requires short product retention time in the reactor. In certain cases, 
cells and/or products can be retained in the reactor, which allows a very high cell density 
and achieves higher protein production than the fed-batch mode [36].  
In comparison to traditional stainless steel and glass bioreactors, a disposable 
bioreactor is a cultivation container which is typically made by FDA-approved 
polymeric materials and discarded after single usage [37]. Consequently, this reduces 
the contamination risk and saves the sterilization and cleaning time which is required 
for stainless steel or glass bioreactors [38]. Meanwhile, disposable equipment allows to 
turn over the manufacturing suite for different products quickly and save manufacturing 
plant floor space a lot. Though limitation still exists for disposable bioreactors, such as 
restricted scalability with a max volume of 2,000-L for most vendors, possible secretion 
of leachables and extractables, etc. [39, 40], it becomes a good option in the 
biopharmaceutical industry. 
1.3.4. Process parameters 
1.3.4.1. Scale dependent parameters 
A). Agitation 
In bioreactors, agitation is required to maintain nutrients well mixed and disperse 
11 
 
gas. Because CHO cells do not possess cell wall to protect themselves from mechanical 
damage. They are more sensitive to shear stress than microbes, even with surfactants 
such as Pluronic-F68 to reduce shear damage [41]. Hence, agitation needs to be 
carefully chosen to ensure sufficient mass transfer while causing little mechanical 
damage to the cells. Maintaining constant agitation throughout cell culture is applicable 
for lab scale bioreactors but may not be suitable for pilot or full scale bioreactors 
because inhomogeneous mixing or cell damage may occur in large scale bioreactors. 
Various strategies are used for the optimization of agitation rate in process scale 
up/down including constant volumetric power, constant impeller tip speed, impeller 
shear rate and specific impeller pumping rate. More recently, multivariate analysis is 
used for agitation optimization during scale-up/-down [42, 43].  
B). Oxygen/air sparging and COR2R stripping  
Oxygen (OR2R) or air is sparged to maintain the necessary sufficient dissolved oxygen 
(DO), while carbon dioxide (COR2R) stripping is applied to adjust the dissolved COR2 Rlevel 
and to further control pH during cell culture. However, excessive sparging can damage 
cells because the cells can attach to the bubbles and get damaged when the bubbles 
burst.[44] Therefor, similar to agitation, sparging strategy needs to be appropriately 
developed. OR2R transfer rate and COR2R transfer rate models based on the two-phase 
dynamic mass transfer kinetics are usually used for sparging strategy optimization 
during scale-up/-down [45, 46].  
1.3.4.2. Scale independent factors 
A). Temperature 
Temperature is one of the key process parameters as almost all the enzymatic 
process within the cells are temperature sensitive. Generally, the optimum temperature 
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for mammalian cell growth is at around 37 °C [47]. Reported temperature range for 
CHO cell culture falls between 30 °C to 42 °C [48, 49]. For the purpose of high 
productivity and biologics quality, temperature may be downshifted during the 
exponential phase [48, 50-53]. This phenomenon was reported to be correlated with the 
increased mRNA levels at reduced temperatures and has been examined by metabolic 
flux analysis [54, 55]. 
B). pH 
A proper pH condition is required to ensure the CHO cells grow and express 
biologics in a comfortable environment [56]. The media pH usually changes slightly 
during the cell culture process and is controlled within a near neutral range by NaR2RCOR3R 
and COR2R [57, 58]. It has also been reported that pH affected cell membrane osmosis 
due to the NaR2RCOR3R added to maintain a neutral extracellular environment [59]. 
Meanwhile, cell thermo-tolerance and its glycosylation pathway can be sensitive to pH 
[60, 61]. This means an accurate pH control is essential to achieve good cell culture 
performance. 
1.3.5. Viable cell density and viability 
The viable cell density (VCD) and cell viability are two parameters indicative of 
cell growth and health. It is crucial to grow the cells to a moderate density and maintain 
the viability throughout the cell culture to achieve high protein titer and quality. Serious 
cell death and viability drop may lead to the release of toxins and enzymes from the 
dead cells, which may further lead to a low protein titer or high protein fragmentation. 
Some cell lines have intrinsically high growth rate and capable of reaching high cell 
density in the culture, while others have lower growth rate and reach lower cell density. 
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Meanwhile, appropriate medium can improve cell growth and maintain high viability. 
1.3.6. Metabolites 
Thousands of metabolites are generated during the cell culture process, among 
which lactate and ammonia are two well-known toxic metabolites [62-64]. Their 
accumulation to high levels negatively impacts on the cell health the protein quality [62, 
65, 66]. The possible mechanisms for these negative effects are the increase in 
osmolality, the intracellular and extracellular microenvironment changes as well as 
some enzymatic processes being affected by the by-product accumulation [67, 68]. 
Therefore, efficient utilization of nutrients to their overflow to lactate and ammonia is 
always desired. 
During cell culture, it is not unusual to observe that lactate and ammonia are 
produced at the early stage and then consumed at the late stage [69].  Such metabolic 
shift from production to consumption usually occurs after the exponential growth phase. 
It may be because of the intracellular enzyme expression change [31]. Such metabolic 
shift has often been observed to correlate with higher productivity, though it is currently 
unknown what exactly triggers it and how to consistently induce it. A number of cell 
culture feeding strategies and new cell lines have been developed to control lactate and 
ammonia at low levels or to induce metabolic shift [62, 70, 71]. 
1.3.7. Protein titer 
As the final output, the recombinant protein titer is one key indicator to evaluate a 
cell culture process. [68, 72, 73]. With the process and facility development in the recent 
years, the global average commercial mAbs titer from upstream bioprocessing has 
14 
 
increased from 0.20 (g/L) in 1985 to 2.56 (g/L) in 2014, and is expected to reach 3.25 
(g/L) in 2024 [74-77]. Table 1 listed the cell culture performance from different cell 
lines, protein types and bioreactor modes. Though different proteins and CHO cell lines 
show various kinetic properties, with a well-developed upstream process at fed-batch 
or perfusion bioreactor mode, Gµ  can reach 0.7 (dayP
-1
P) level with a high productivity 
Pµ  up to 20.1 (pg cellP-1P dayP-1P), and very high peak cell density, up to 200 × 10P6P 
(cells/mL) (Table 1) [64]. Some biologics such as bi-specific mAbs and antibody-drug 
conjugate may have slightly lower titer than the mAbs listed in Table 1-1 [5].  
 
Table 1-1. Relevant bioprocess parameters (peak value) for interferon, Fc fusion protein 
and other mAbs expression from CHO cells 
Therapeut
ic protein 










interferon CHO-K1 2.6 0.75 – 1.2 0.36 – 
0.65 
Batch 2010 [78] 
unknown 1.3 – 4.2 0.95 – 3.5 NA 2005 [79] 
CHO-K1 0.35 - 0.8 0.15 0.48 Fed-
Batch 
2008 [80] 
CHO-K1 3.7 2.6 0.48 Perfusion 2010 [78] 
Fc fusion CHO-K1 > 4 2 - 18 0.6 – 0.7 Fed-
Batch 
2015 [81] 
CHO-DG44 5.8 - 7.8 9.2 - 20.1 0.51 – 
0.66 
2014 [64] 
mAbs CHO-DG44 8.5 > 50 0.7 Batch 2015 [8, 9]  





27 – 33.5 > 2 NA Perfusion 2005 [82] 
unknown 110 - 200 9 - 15 NA 2013 [83] 




1.4. Kinetic Modeling 
1.4.1. General principles 
It is known that numerous dynamic metabolic as well as mass and heat transfer 
processes occur simultaneously during cell culture [84]. Quite a few cell culture 
characterizations need to be optimized at limited time to reach good productivity and 
quality [85]. To speed up the process development, kinetic modeling can be used as a 
mathematic tool to simulate the cell culture process, analyze and optimize the various 
process parameters to reduce the time and resources [86].  
Conventional kinetic modeling strategies for cell culture heavily depend on 
intuitional observation and empirical knowledge. These purely empirical or completely 
unstructured models are regarded as “black box” which is commonly applied for 
simulating cell culture process in the manufacturing [87]. They are easy to use and can 
be adapted for data fitting. However, the “black box” kinetic model parameters tell little 
cell metabolism information, and are prune to fail in optimizing cell culture process.  
Thanks to the fast development of the cell metabolic mechanism research and 
computer technology, more mechanistic modeling strategies have been developed. 
Though fully mechanistic kinetic modeling strategy which involves thousands of 
enzymatic processes is still a heavy load even for a super-computer, building up a 
practical ‘grey box’ strategy can be a meaningful step forward currently. Practical ‘grey 
box’ models can be developed based on the updated cell metabolic knowledge, cell 
culture observations and empirical knowledge. As such, they are able to tell some key 
cell metabolism information, to predict the cell culture performance under extended 
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conditions, to uncover the possible optimized processes, and to maintain the 
conventional modeling function of summarizing the large volume of experimental data 
[87].  
Generally, there are four steps in the framework of macroscopic cell culture kinetic 
modeling (Fig. 1-3) [88]: general mathematic model development, data analysis, model 
validation and refinery, as well as model based process strategy development. Among 
all these steps, mathematic model building is the most crucial part, which directly 





General Model Development 
a) Model structure defined based on cell lines and experiment systems 
b) Physiological ranges for each kinetic parameter value estimation based on 
metabolic processes, experiment conditions and literature data  
Step 2 
Data Analysis 
a) All the required observations in kinetic models collected during the 
experiment 
b) Collected data computed with the general model and pre-estimated data 
c) Kinetic parameters refined within a physiological reasonable range 
d) Group the “influential” and “non-influential” items 
Step 3 
Model Refinery and Validation 
a) Models refined with “influential” items 
b) Models validation with optimized  kinetic parameters 
Step 4  
Process development 
a) Metabolic process based analysis on crucial parameters 
b) Model predictive capability check with independent dynamic experiments 
c) Process control strategy optimization and prediction based on validated 
kinetic analysis 
Fig. 1-3. Framework for macroscopic kinetic modeling strategy of CHO cells. 
      
1.4.2. Current kinetic models 
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Focusing on the important cell culture factors, only key rate-limiting steps deserve 
kinetic modeling consideration among thousands of intracellular metabolic reactions. 
Different kinetic models have been applied to describe the cell culture, correlate 
detectable substrate and metabolite profiles. A summary of CHO cell culture related 
kinetic model types are listed in Table 1-2. As reported, the Michaelis-Menten (M-M) 
Equation, Hill Equation, Ordered Binding, Monod-Wyman-Changeux Model (MWC) 
[89, 90] and Mechanistic Kinetic Model, etc. are the popular models reported and 
applied [91, 92].  
The M-M Equation has been the preferred modeling methods in many cell culture 
and enzyme kinetic studies due to its convenience for calculation [93-95]. This method 
simplifies the cell unit as a mono-enzyme, which catalyze the nutrients to the products. 
It is applicable at a single substrate limiting condition for illustrating cell growth. 
However, when multiple metabolic pathways become limiting, M-M Equation is not 
adequate. A comprehensive format of M-M Equation involving multiple substrates and 
inhibitors was reported as an improved approach [85, 96], though significant deviation 
can be observed at wide nutrient ranges [97]. 
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Table 1-2. Kinetic models applied in CHO cell culture processes  












































































































































































dSADr =  
NA [102] 
 
By introducing the Hill Coefficient, better simulation results than those using the 
M-M Equation were reported [103]. However, kinetic parameters lose their mechanistic 
information due to the forcible introduction of the empirical Hill Coefficient. This 
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shortcoming makes the Hill Equation only empirically applicable for data manipulation 
or regression [104].  
Binding Models are more mechanistic models than the M-M and Hill Equations. It 
was derived based on the ordered or random molecule collision occurred intracellularly 
[102]. This model considered multiple substrates involved in one metabolic pathway. 
However, for those rate-limiting reactions catalyzed by interactive oligomeric enzymes, 
it fails to take the enzyme allosteric effect into consideration [105]. Therefore, the 
validity of simulation results via this model is limited within narrow substrate 
concentration ranges.  
Via taking the interactive properties of key enzymes into consideration, MWC 
Model and Mechanistic Kinetic Model are able to better simulate the enzymatic 
pathways and cell culture [90, 98], though it is still at infant stage in applying these two 
modeling methods with few publication reported. MWC model assumes the enzyme 
molecules exist as a mixture of two states, exhibiting different ligand binding affinities. 
Mechanistic kinetic model assumes the enzyme binding affinity and catalytic activity 
change with different amount of substrate or product ligands binding on the oligomeric 
enzymes [106]. These two models are more adequate to reflect the nature of 
intracellular metabolic activities than the above discussed model types. However, they 
involve more kinetic parameters (Table 2) which means more sampling and analysis 
work are required to develop the kinetic model. 
All the above kinetic models have their advantages and drawbacks, none of them 
is perfect for all situations. Table 1-3 summarized the reported modeling methods used 
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for different central metabolic and mass transfer processes illustrated in Fig. 1-1. The 
selection of modeling strategies based on two principles: 
A). Empirical modeling methods are recommended for mass transfer and single 
substrate-limited processes; while mechanistic modeling methods are more applicable 
for interactive oligomeric enzymes catalyzed or multiple rate-limiting reactions 
involved processes. 
B). Empirical modeling methods with less kinetic parameters are recommended for 
a fast operation condition screening and a rapid view of the cell line or process 
properties; while mechanistic modeling methods with more kinetic parameters are 
preferred for adequate optimization of the cell culture parameters to achieve excellent 
performance as well as for trouble shooting to understand the metabolic mechanism.  
To get a desired results as well as to balance the time and resource, the utilization 




Table 1-3. Metabolic kinetics of selected pathways  
Metabolic 
process 










][ 0  Facilitated Diffusion [102] 
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Gµ=  Cell culture substrate 
































































































































































































































































































































































P, PbP and PcP indicate the equations are applicable for no inhibitor, competitive inhibitors and non-
competitive inhibitors situations, respectively.  
 
1.4.3. Kinetic properties of CHO cell culture 
Table 1-1 presents a literature example of CHO cell culture at different conditions. 
The kinetic characteristics are influenced by the properties of cell lines, cell culture 
processes and therapeutic proteins. As discussed above, perfusion mode always allows 
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a high peak VCD and higher productivity, though the manufacturing cost is also higher 
than the conventional batch and fed-batch modes. Meanwhile, when expressing mAbs, 
the cell growth and protein titer were observed higher than that when expressing Fc 
fusion and interferon.  
1.4.4. Scale-up modeling 
Scale-up/-down is an integral part of cell culture. Scale-up bridges the lab-scale 
knowledge to manufacturing [43, 48]. Scale-down is important for simulating the 
manufacturing scale performance at lab-scale for research, trouble shooting and process 
development purposes in order to save time and cost [42]. In a pilot or full scale 
bioreactor, the scale independent parameters can be controlled relatively coincident as 
that in a lab scale bioreactor, while the scale dependent parameters need to be 
appropriately developed. 
Successful translation of a cell culture process across different scales require 
careful consideration of scale up/down strategies. In general, physical conditions in a 
large bioreactor cannot exactly duplicate those in a small bioreactor although geometric 
similarity is maintained [102]. Several phenomena are unique to large scale which are 
not typically observed at lab scale such as limitations on rates of agitation and COR2R 
stripping. Various models are currently available to evaluate the effect of scale and to 
guide scale-up/-down strategies. A summary of the scaling criteria for suspension cell 
cultures at similar geometric bioreactors are listed in Table 1-4. While volumetric 
energy input and impeller top rate are more applied for microbial process development, 
CHO cell culture scale-up/down is much based on volumetric mass transfer constant 
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and oxygen or carbon dioxide transfer rate.  
 
Table 1-4. Summary of scaling criteria for suspension cell cultures [43] [102, 115] 
Scaling criteria Notation 
Volumetric energy input VDNVP p // 53ωρ=  
Tip velocity Dω  
Specific impeller pumping rate ω∝VQ /  
Volumetric mass transfer constant βαω qakL ∝   or 
βα )/()/( SQVPak GL ∝  
Reynolds Number µρω /Re 2D=  
Oxygen uptake rate 
























Where, PR0R is the impeller power; ω is the impeller rotation number; D is the impeller 
diameter; V is the working volume; NRPR is the impeller power number; kRLRa is the volumetric 
mass transfer constant; q is the sparing rate; α, β and a, b are the empirical coefficients; QRGR is 
the gas volumetric rate; S is the tank cross-sectional area; RReR is the Reynolds Number; ρ is the 
medium density; μ is the medium viscosity; *
LC  and LC  are equilibrate and dynamic dissolved 
oxygen concentration, respectively; *
2CO
C  and 
2CO
C  are equilibrate and dynamic dissolved 
carbon dioxide concentration, respectively.  
 
1.5. Case Studies-medium optimization 
As discussed above, medium design is one crucial task for cell culture. Among all 
the nutrients, carbohydrates are the main carbon and energy source which should be 
well optimized. Numerous researches on this topic have been carried out in the recent 
decades [22, 63, 116, 117], while few of them are well analyzed with kinetic modeling 
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method. With appropriate modeling, new knowledge can be extracted from researches 
reported even 18 years ago [22], which was confirmed after 6 and 10 years of the 
original publication via other independent researches [70, 71]. 
In this chapter, the experimental data are taken from Altamirano et al. (2000) [22], 
who reported also semi-quantitative comparison results. In the experiment, CHO-
TF70R cell culture was cultivated for t-PA production. The culture was carried out with 
7 mM amino acids and 20 mM monosaccharides, a stirring rate of 50 rpm with 96% 
relative humidity in an atmosphere of 5% COR2R in air. The cell culture was conducted in 
spinner flasks in a COR2R incubator at 37 °C. To get the kinetic information, the original 
experimental data were reanalyzed with the modeling strategies listed in Table 1-3. The 
simulation was carried out with the Excel Visual Basic program ODExLims. The 




Table 1-5.Selected values of the cell culture kinetic characterizations for CHO-TF70R 
cell line growing on different carbohydrates and amino acids sources. 
Amino acids Glutamine Glutamate 
Monosaccharides Fructose Mannose Glucose Galactose Glucose Galactose 
Gµ  (10P
-3
P hP-1P) 0~13 2.6~31 2.2~26 0~13 8.6~27 7.2~21 
dµ  (10P
-3





0~59 1.2~56 0~48 0~57 12~46 8.5~71 
 
The cell was cultivated with glutamine and four different monosaccharides. The cell 
culture processes were well simulated (Fig. 1-4). It shows that mannose and glucose 
could achieve the highest peak while fructose had the poorest performance. The 
outstanding effect from mannose and glucose was confirmed with the large µRGR shown 
in Table 5. However, the computed µRGR of galactose and fructose are similar. The higher 
peak VCD from galactose than fructose was due to the smaller µRdR. Comparing the cell 
growth properties (µRGR and µRdR) of all these four monosaccharides on cells, mannose and 
glucose provided the high cell growth ability, while glucose and galactose also inhibited 
cell death the most. Thus, glucose was the best choice for cell growth. 
Shown in Fig. 1-4, mannose achieved the highest protein titer, while a computed 
results of µRpR (Table 1-5) shown that mannose, fructose and galactose actually presented 
similar protein production ability from each cell, slightly higher than glucose. This 
points to a possible combination of two monosaccharides in the media at different 
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stages to achieve high protein titer. For example, it may be applicable to use a high 
glucose ratio media for biomass accumulation in the exponential phase and feed in high 
galactose, fructose or mannose ratio medium when the cells enter therapeutic protein 
expression stage. This strategy was later proposed in 2006 [71] and 2011 [70] by other 
independent researchers, though it could be calculated from the Altamirano’s 


















































































































































Fig. 1-4. Profiles of CHO-TF70R cell culture for t-PA production with different 
carbohydrates: (A) VCD; (B) Monosaccharides; (C) Glutamine; (D) Lactate; (E) 


























































1.6. Challenges and perspectives of kinetic modeling for CHO cell culture 
upstream process development  
Despite the rapid development of CHO cell kinetic modeling in the recent years, 
the models keep updating with new discoveries from mammalian cell metabolic and 
genetic engineering researches. Thus, it is challenging to set up standard models that 
can be used for one decade or applicable for most of the current research projects with 
different purposes. Theoretically, kinetic modeling is able to elucidate the mechanism 
of the protein quality attributes. However, a better understanding of the quality attribute 
mechanism may be required to build up the models. Meanwhile, with the application 
of perfusion and single-use technology, it is necessary to validate the applicability of 
the kinetic characteristics from the stainless steel batch or fed-batch bioreactors. 
In order to better serve cell culture, further improvement of kinetic modeling may 
combine it with other technologies to form a powerful platform methodology. For 
example, metabolic flux analysis can be used for dynamic metabolic information 
detection.[118] This detail information can help to understand the metabolic 
mechanism and build up models to elucidate the quality attributes. Also, the utilization 
of powerful supercomputer makes it possible to compute more kinetic processes within 
reasonable time. This may allow rapid on-line kinetic analysis in the future, which can 
be a strong tool for process automation, monitoring and fast metabolic disorder 




In this work, crucial cell culture factors were reviewed and kinetic modeling 
principles and strategies were systematically summarized. One case study was 
presented to give an examples of medium optimization via kinetic modeling. Though 
kinetic modeling is not a current obligatory part for documentation by FDA, it is 
definitely beneficial for data analysis, process prediction, trouble shooting, and scale-
up/-down. With the awareness of its importance and the continuous development of 
kinetic modeling, it is potential to be an efficient and practical tool for the process 
development and manufacturing in the near future. Future cell culture kinetic modeling 
research may combine with other technologies to form a standard and powerful 
platform tool to better serve the biopharmaceutical industry. 
While this chapter provides a general introduction of kinetic modeling principles, 
the following chapter will focus on the discussion of current biopharmaceutical industry. 





Screening of Monoclonal Antibodies for Cancer Treatment 
2.1.Abstract 
The global biologics market is growing rapidly. The screening process of suitable 
biologics and indications is important to design appropriate pre-clinical, clinical and 
marketing strategies. A general definition of ‘screening’ in the biopharmaceutical 
industry includes three aspects: the appropriate biologics for the specific cancers, the 
appropriate indications for the specific biologics, and the promising biologic candidates 
from the pools at the pre-clinical drug discovery stage. Effective screening strategies in 
the biopharmaceutical industry are crucial to accelerate the drug commercialization 
process and select the effective biologics for patients. The current status of commercial 
mAbs and the global pharmaceutical market was briefly summarized in this chapter. 
The mechanism of commercial mAbs and the indications, as well as the current 
technologies for mAbs screening in the new drug discovery and cell line development 
stages were systematically reviewed. This work aims at being a beneficial reference for 
screening high-quality mAbs, appropriate indications with efficient technologies.  
 
Keywords: screening, cancer treatment, biomarker, monoclonal antibodies. 
2.2.Introduction 
Cancer is a global leading cause of death [119]. It is featured as unregulated cell 
division and growth [120]. Caused by genic mutation or gene expression disorder, 
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abnormal metabolism can be observed within cells [121]. While gene therapy is still 
away from well accepted by FDA, monoclonal antibodies (mAbs), as one of the major 
parts of biologics, are currently widely recognized drugs for conservative cancer 
treatment. The mAbs are antibodies made by identical cells, which are all derived from 
a unique parent immune cell [122, 123]. The history of mAbs can be traced back to 
1975 when recombinant DNA technology was applied to antibody design [124]. The 
first mAb approved by FDA was OKT3 in 1986 [125], though it took almost three 
decades to the current ‘golden age’ of cancer therapies using mAbs [126]. Now, nearly 
a hundred commercial mAbs are available in the global market while hundreds of 
candidates are in the clinical trials. 
The biopharmaceutical industry is regarded, as a matter of fact, a high risk and high 
revenue industry. On average, it takes $1.2 to $ 4 billion and 10 to 12 years for one 
biologic candidate to be approved and enter the market from the very beginning. From 
the risk point of view, less than 0.1 % of the biologic candidates before CMC stages are 
able to enter into Phase Ⅰ. Among those biologics, 60 % fail to pass Phase Ⅱ, while 
there’s another 50% failure risk at the clinical stage Phase Ⅲ. In addition, there are 
significantly higher risks at earlier new drug discovery stages. Thus, an efficient and 
successful screening of mAb candidates and corresponding indications is crucial. The 
word “screening” in the biopharmaceutical industry refers to three aspects: 
A). Screening of drug or biologic candidates for specific diseases; 
B). Screening the potential indications for specific drugs or biologics; and 




Undoubtedly, all the aspects are definitive for the destiny of one biologic candidate. 
In this chapter, the current commercial mAbs and the recognized biomarkers were 
systematically reviewed. The principles, criteria, modeling and detection methods of 
biologics screening were presented and compared. It aims at providing comprehensive 
screening information for cancer treatment, which is potentially beneficial for research 
institutes, pharmaceutical companies, and patients.  
 
2.3.Mechanism 
It is known that one distinctive characteristics of cancer from other diseases is that 
immune cells have difficulties to distinguish tumor cells from normal cells [123]. 
Therefore, a process that can either assist the immune cells to identify the tumor cells, 
or stimulate the immune cells to be more active is potential for cancer treatment. MAbs, 
which are designed for distinguishing the biomarkers specifically expressed by tumor 
or immune cells, are recognized as promising biologics. Though the exact metabolic 
details of how mAbs work is awaiting better understanding, the general mechanism 
typically falls into two categories: 
A). mAbs distinguish and bind the biomarkers abnormally expressed by the tumor cells, 
helping the immune cells or the drugs to target these cells. For example, trastuzumab, 
which was designed to target the biomarkers HER2, is a representative commercial 
mAb for breast cancer. 
B). The immune cells are activated by mAbs to attack the tumor cells. Successful 
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commercialized examples, such as nivolumab and pembrolizumab which target PD-1 
and PD-L1 biomarkers; respectively, were designed based on such a mechanism. 
With the development of cancer mechanism understanding, hundreds of biomarkers 
have been detected, and some of them have been used for mAbs design. Table 2-1 listed 
47 recognized biomarkers that have been successfully used for commercial mAbs. 
Indications that relate to the abnormal expression of these biomarkers have been well 
studied. This table aims to help narrow down the screening scope of the mAbs and 
indications, as well as predict the clinical results and control the quality of the designed 
protein therapeutics, which is in compliance with the Quality by Design (QbD) 
principles. This information may help biopharmaceutical industry to make decisions on 





Table 2-1. The recognized biomarkers for biologics and the approved indications 
Antigen Biomarkers Indications Ref. 
α-4 integrin Multiple sclerosis [127] 
BLyS Systemic lupus erythematosus [128] 
CCR4 Relapsed or refractory adult T-cell leukemia/lymphoma 
[129] 
CD3 Transplant rejection, organ [130] 
CD6 Psoriasis, Arthritis, rheumatoid [131] 
CD19 Precursor B-cell acute lymphoblastic leukemia [132] 
CD20 
Relapsed or refractory low-grade, follicular, or 
transformed B-cell non-Hodgkin's lymphoma, 
chronic lymphocytic leukemia, and multiple 
sclerosis 
[133] 
CD30 Hodgkin lymphoma, and anaplastic large-cell lymphoma 
[134, 
135] 
CD38 Multiple myeloma [136] 
CD52 B-cell chronic lymphocytic leukemia [137] 
Clostridium difficile 
toxin B 




component 5 Paroxysmal nocturnal hemoglobinuria 
[139] 
CTLA-4 Metastatic melanoma [140] 
Dabigatran Emergency reversal of anticoagulant dabigatran [141] 
EGFR Metastatic colorectal carcinoma, and metastatic squamous non-small cell lung carcinoma 
[142, 
143] 
EpCAM Malignant ascites, multiple cancers [144] 
F protein of RSV Respiratory syncytial virus [145] 
Ganglionside P3 Multiple cancers [146] 
GD2 Pediatric high-risk neuroblastoma [147] 
GPIIb/IIIa Percutaneous coronary intervention [148] 
HER2 Metastatic breast cancer [149] 
IgE Moderate to severe persistent asthma [150] 
IL12 Plaque psoriasis [151] 
IL23 Psoriatic arthritis, plaque psoriasis, and crohn's disease 
[151, 
152] 
IL17A / IL17RA Plaque psoriasis [153] 
IL1B Cryopyrin-associated periodic syndrome [154] 
IL2R Multiple sclerosis [155] 
IL2RA Prophylaxis of acute organ rejection in renal transplant 
[156] 
IL4RA Atopic dermatitis [157] 
IL5 Severe asthma [158] 
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IL6 Multicentric Castleman's disease [159] 
IL6R Rheumatoid arthritis, and systemic juvenile idiopathic arthritis 
[160] 
IL8 Psoriasis [161] 
integrin receptor Ulcerative colitis, crohn's disease [162] 
PCSK9 Heterozygous familial hypercholesterolemia, and refractory hypercholesterolemia 
[163] 
PD-1 Metastatic melanoma, and metastatic squamous non-small cell lung carcinoma 
[164-
166] 
PD-L1 Urothelial carcinoma, metastatic non-small cell lung cancer, and metastatic Merkel cell carcinoma 
[167, 
168] 
PDGFRA Soft tissue sarcoma [169] 
Protective antigen of 




PSMA Diagnostic imaging agent in newly diagnosed prostate cancer or post-prostatectomy 
[171] 
RANKL Postmenopausal women with osteoporosis [172] 
SLAMF7 Multiple myeloma [173] 
TNF 
Rheumatoid arthritis, juvenile idiopathic arthritis, 
psoriatic arthritis, ankylosing spondylitis, crohn's 
disease, ulcerative colitis, and plaque psoriasis 
[174, 
175] 
TNF α Crohn's disease [174] 
VEGF Metastatic colorectal cancer [176, 177] 
VEGFR1 Wet age-related macular degeneration [178] 




2.4.Design Technologies Selection 
Unlike small molecule drugs that can directly enter cells and interrupt the 
metabolism with poor capacity of discernment, mAbs are mild and impact indirectly on 
the metabolic pathways with excellent targeting ability on tumor cells. To improve the 
efficacy as well as avoid patent disputes, several advanced design technologies have 
been applied to improve mAb performances. The characteristics of different biologic 
design technologies are briefly summarized in Table 2-2, which were further discussed 
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as follows.  
 











Conventional Low 2 – 10 60 – 80 Normal 
ADC Medium 0.4 – 5 50 - 70 Small & Large 
Molecule 





High Depends Depends Synergistic 
Effect 
 
2.4.1. Antibody Drug Conjugate 
Antibody drug conjugate (ADC) technology is one improvement strategy, which 
allows small molecules conjugated on an antibody molecule [180]. Via the excellent 
targeting ability of the protein therapeutics, the small molecule is able to directly 
interrupt the metabolic pathways of tumor cells with significantly improved capacity of 
discernment [181]. Nevertheless, challenges that ADC faces in manufacturing include: 
1. Unstable expression level due to the variety of the link structure, especially, when 
the link consists of unnatural amino acids; 
2. Low downstream yield due to the added purification steps after the conjugation of 
the small molecule drug to the protein molecule. 
2.4.2. Bi-specific 
Bi-specific antibody technology is another option for better biologics design. It 
allows one biologic molecule to recognize two biomarkers simultaneously. 
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Theoretically, the combination of the two biomarkers should fall into one of the three 
types: both on tumor cells, both on immune cells, and one on tumor cell and one on 
immune cell. Nevertheless, the third design is the most preferred in the industry. By this 
design, the immune cells can be effectively activated, then rapidly and adequately attack 
the tumor cells in situ [182]. This makes the protein therapeutics exhibit synergistic 
effect compared to using two or more independent mAbs. This technology has the 
potential to enhance the efficacy while reducing the biologics dosage and side effects. 
However, bi-specific molecules also have their drawbacks in manufacturing, such as: 
1. Low expression level during cell culture due to the high risks of chain mispairing 
and protein aggregation; 
2. Low downstream separation efficiency because of the similar physicochemical 
properties of the mispairing molecules.  
2.4.3. Combined Medication 
Combined medication technology is an alternative choice to improve the efficacy. 
The joint usage of two or more biologics, or biologics with small molecule drugs has 
the potential to exhibit synergistic effect on tumor cells, because different biologics 
and/or drugs may impact on different metabolic pathways. This technology provides 
one strategy to screen new indications for existing mAbs avoiding huge investment for 
new drug design and application. This strategy, however, has some disadvantages for 
commercialization, including: 
1. Significantly high cost in manufacturing, factory operation, storage, and supply 
chain management for different products/molecules; 
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2. Difficulties in maintaining acceptable stability of different biologics and/or drugs if 
in one formulation; 
3. Inconvenience and high cost in drug delivery if different formulations were used 
for different biologics/drugs.  
 
2.5.Commercial mAbs 
With increasing attention being focused on mAbs, a large amount of investment has 
been attracted into the biopharmaceutical industry for biologics commercialization. Fig. 
2-1 lists the top 10 best-selling mAbs in 2016 and their global annual sales from 2014 
to 2016. The data were obtained from the annual reports of these enterprises. Little rank 
change was observed in Fig. 2-1, except Opdivo was regarded as a dark-horse in the 
recent years due to the excellent performance of this anti-PD-1 mAb. Humira, 
Remicade, and Rituxan kept the top three best-selling for the recent three years (Fig. 2-
1), bringing considerable revenue to Abbvie, Johnson & Johnson, and Roche, 
respectively. In 2016, the total sales of these ten mAbs were $ 61.2 billion, which is 
almost 70% of the whole global antibody market. The global oligopolistic market 
landscape may not be broken in the next few years due to limited number of validated 





Fig. 2-1 Top 10 best-selling mAbs in 2016 and their global annual sales in the recent 
three years. Different colors refer to the selling data in different years. 
 
A list of biomarkers with corresponding commercial mAbs and patent holders were 
shown in Table 2-3. The mAbs and patent information was filtered manually from an 
open source tool called ‘Citeline Service’ before July 16PthP, 2017. Most of the biosimilars 
currently in research were designed based on these listed mAbs. This table also includes 
the major biomarkers for ADC and bi-specific antibodies, which is a trend for biologic 
design in the next few years. 
 
Table 2-3. Commercial biologics and the corresponding antigen biomarkers, patent 





























Antigen Biomarkers Biologics Patent Holders BLA 
Approved 
α-4 integrin Tysabri Biogen Idec 11/23/2004 
BLyS Benlysta Human Genome Sciences 03/09/2011 
CCR4 Poteligeo Amgen 03/30/2012, Japan 
CD6 Alzumab Center of Molecular Immunology 
01/07/2013, 
India 
CD19 Blincyto Amgen 12/03/2014 
CD20 






Arzerra Glaxo Grp  11/26/1997 
CD30 Adcentris Seattle Genetics 09/19/2011 






toxin B Zinplava Merck 10/21/2016 
Complement component 
5 Soliris Alexion 03/16/2007 
CTLA-4 Yervoy Bristol-Myers Squibb 03/25/2011 
dabigatran Praxbind Boehringer Ingelheim 10/16/2015 
EGFR 
Erbitux ImClone Systems 02/12/2004 
Portrazza Eli Lilly 11/24/2015 





Theraloc Oncoscience 11/12/2003, EMEA 














F protein of RSV Synagis Med-Immune 06/19/1998 






GD2 Unituxin United Therapeutics 03/10/2015 











Janssen Biotech 09/23/2016 
IL17A 
Taltz Eli Lilly 03/22/2016 
Cosentyx Novartis 01/21/2015 
IL17RA Siliq Valeant 02/15/2017 
IL1B Ilaris Novartis 06/17/2009 
IL2R Zinbryta Biogen 05/27/2016 
IL2RA 
Simulect Novartis 05/12/1998 
Zenapax Roche 12/10/1997 
IL4RA Dupixent Regeneron 03/28/2017 
IL5 
Nucala GlaxoSmithKline 11/04/2015 
Cinqair Teva 03/23/2016 





Kevzara Sanofi 02/01/2017, Canada 
IL8 ABCreamPa Yes Biotech 07/13/2004, China 
integrin receptor Entyvio Takeda 05/20/2014 
PCSK9 
Praluent Sanofi Aventis 07/24/2015 
Repatha Amgen 08/27/2015 
PD-1 
Opdivo Bristol-Myers Squibb 
12/22/2014 
03/04/2015 





Bavencio EMD Serono 03/23/2017 
Imfinzi AstraZeneca 05/01/2017 
PDGFRA Lartruvo Eli Lilly 10/19/2016 
Protective antigen of 
Bacillus anthracis Raxibacumab 
Human Genome 
Sciences 12/24/2012 
Protective antigen of the 
Anthrax toxin Anthem Elusys Therapeutics 03/18/2016 
PSMA ProstaScint Cytogen 10/28/1996 




SLAMF7 Empliciti Bristol-Myers Squibb 11/30/2015 
TNF 
Humira Abbvie 12/31/2002 
Amjevita Amgen 09/23/2016 
Cimzia UCB (company) 04/22/2008 
Simponi Centocor 04/24/2009 
Simponi Aria Janssen Biotech 07/18/2013 
Renflexis Samsung Bioepis 04/21/2017 
Inflectra Celltrion Healthcare 04/05/2016 







Cyramza Eli Lilly 04/21/2014 
Note: “PaP” refers that it is the generic name of the biologics instead of the commercial name.  
If the BLA was not approved by FDA, the biologics was specified with its approved location or 
organization. 
 
2.6.mAbs Screening Methods 
2.6.1. Screening criteria 
After the designing of the mAbs based on the mechanisms discussed above, there 
could still be thousands of candidates available. This will be followed by two major 
screening processes to obtain best performed antigen-specific antibodies from the pool, 
which are:  
1. Binding screening including specificity [183] & affinity [184]; 
2. Functional screening including cell growth, proliferation, apoptosis, endothelial 
tube formation, etc. [185]  
While the functional assays are based on different disease models, the binding screening 
assays are universal in biopharmaceutical industry. 
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Specificity is the ability of the antibody binding to its cognate antigen and not to 
other targets. Affinity is the characteristic of antibody-antigen binding strength. These 
two criteria are crucial to ensure the efficacy, while good specificity can minimize the 
side-effects and good affinity is well preferred to reduce the drug dosage.  
Functional activities are often the most significant characteristics of an antibody, 
including ability to deliver a toxin, antagonist activity, partial and full agonist activity, 
etc. These activities are often related to the protein allostery via the antigen-antibody 
specific binding [186, 187]. 
2.6.2. Screening Models 
To quantitatively evaluate the above criteria, kinetic modeling strategies are usually 
applied [188]. Known models include Michaelis–Menten (M–M) model [189], Hill 
Equation [94, 190-192], different types of Binding Models [105, 193, 194], Morpheein 
Model, Monod–Wyman–Changeux (MWC) model [99], Mechanistic kinetic 
description strategy [101], and empirical models derived from software such as JMP 
[195]. The advantages and drawbacks of each modeling strategy have been discussed 
in chapter 1. 
Table 2-4 presented a summary of the above models with their typical mathematic 
formula and applicable scopes. In the current biopharmaceutical researches, M-M 
Model and Hill Equation are the favored modeling strategies for biologics screening, 
due to their simplicity. While Morpheein Model, MWC Model and Mechanistic kinetic 
description strategy are able to well describe the kinetic properties of the molecular 
interactions. They are preferred when the kinetic mechanism understanding is critical 
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to explain the biologics behavior. Different types of Binding Models can be applied for 
multiple molecules involved reactions, such as bi-specific antibody involved reactions. 
Different strategies are selectively used based on the study purposes and research 
limitations. 
 
Table 2-4. Reported kinetic modeling strategies for molecular interaction study. 





=  non-interactive 















































































































































































2.6.3. Binding Screening Assays 
Enzyme-linked immunosorbent assay (ELISA) is one of the most popular platform 
technologies to identify antigen-antibody complex and both qualitatively and 
quantitatively evaluate the binding strength. The basic principle of ELISA based on 
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radioimmunoassay techniques dates back top 1941 [200], and the exact method was 
created in 1971 [201]. Currently, it is a major detection method for biologics screening, 
because it is simple, quick, sensitive, specific, and high-throughput [202]. Another 
screening technology is surface plasmon resonance (SPR) biosensor [203]. As a gold 
standard for real-time and label-free monitoring technology of biomolecular 
interactions, it is able to determine the thermodynamic and kinetic properties of specific 
molecular interactions [204]. 
While ELISA and SPR are the common techniques for extracellular or cell-free 
antigen-antibody binding detection, fluorometric microvolume assay (FMAT) and 
fluorescence-activated cell sorting (FACS) are well-developed methods for on-cell or 
native binding screening [205]. The working principle based on antibodies binding to 
the antigen expressed on cell surface, and the immunoglobulin constant region of the 
antibodies is detected by a fluorescently conjugated secondary antibody. As a high-
throughput cell-based assay in the hybridoma screening, FMAT and FACS based 
technologies significantly improved the screening efficiency and success probability.  
 
2.7.Conclusion 
Though cancers are not incurable disease due to the rapid technology development, 
they are still a leading threat for human health. In this chapter, the recent trends and 
technologies of mAb development are comprehensively summarized. The information 
of biomarkers, indications, commercial mAbs and the pattern status were systematically 
reviewed. It is beneficial for biopharmaceutical industry, research institutes and patients 
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to make decisions. It aims at providing a comprehensive understanding of the biomarker, 
indication and mAb screening strategies. This may promote further advancements in 
new drug discovery, novel indications of exiting drugs, as well as joint usage of mAbs 
and other cancer treatment methods. 
Based on the above two chapters, the kinetic modeling knowledge and the 
biopharmaceutical industry have been introduced. The following chapter will give a 
case study of the kinetic modeling application for cell culture process development to 






Development of Temperature Shift Strategies for Chinese Hamster Ovary Cell 
Culture Based on Kinetic Modeling 
3.1.Abstract 
Improving cell growth and titer of recombinant protein is crucial in 
biomanufacturing. To achieve this goal, temperature shift (TS) strategies are widely 
used. Though some studies have been published regarding the temperature’s effect on 
Chinese hamster ovary (CHO) cell culture, there is no systematic method of TS strategy 
development available. In this work, the temperature impact was systematically studied 
using two industrial CHO cell lines for production of two model monoclonal antibodies. 
Short-duration experiments with kinetic modeling were applied for rapid TS strategy 
development. Kinetic parameters derived from the resulting experimental data were 
subsequently used to compute the cell culture performance at extended periods. This 
study aims at developing an efficient method for systematic CHO cell bioprocess TS 
optimization to reach a high titer and appropriate cell growth, while providing an 
understanding of temperature’s effect on cell culture performance and quality attributes. 
 
Keywords: Chinese hamster ovary cell culture; kinetic modeling; monoclonal antibody; 




Chinese Hamster Ovary (CHO) cell lines are prevailing hosts for therapeutic protein 
production in the biopharmaceutical industry [3, 4]. Temperature control, as an 
important bioprocess factor [206], remains a topic of great interest for CHO cell culture 
[48, 50-53, 207, 208]. Temperature shift (TS) to a hypothermic condition during the 
exponential growth phase is one favorable strategy to balance cell growth, protein 
expression, and quality [209-211]. Such a strategy holds the potential to improve cell 
culture performance for a prolonged period [207]. However, few models to design TS 
strategies have been reported [212]. Furthermore, current methods of TS strategy 
development require substantial resource investment into laboratory experiments, 
which heavily relies on non-systematic application of empirical knowledge. This 
presents a challenge because it requires exhaustive experimental investigation to 
identify the optimum TS strategy. Therefore, an efficient method to quantitatively 
evaluate temperature effect and to systematically screen TS strategies is beneficial for 
time sensitive process development in the biopharmaceutical industry. 
Kinetic modeling provides a mathematic method to simulate, analyze, and predict 
cell culture processes [96, 102, 213]. Structured models which mechanistically contain 
complete cell culture metabolism information are able to explicitly illustrate the cell 
metabolism [96] and the enzymatic reactions [98]. However the complexity of 
intracellular processes as well as the involvement of hundreds of chemicals and 
reactions makes it difficult to apply this class of model in CHO cell culture [214]. 
Therefore, unstructured models, such as Monod type relationships are widely used to 
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describe CHO cell culture [96, 215-219]. Unstructured models partially characterize 
cell culture properties utilizing measurements such as cell density, nutrients, and 
metabolites while neglecting complex intracellular metabolism. The parameters can be 
used to indicate the activities of considered metabolic pathways, and utilized to evaluate 
the cell culture performance at extended conditions. 
In this study, batch and fed-batch CHO cell culture experiments were conducted to 
estimate kinetic parameters. It is concluded that before the exhaustion of nutrients, 
batch and fed batch modes give similar cell culture performance characteristics due to 
similar intracellular metabolism, except higher cell density and volumetric titer 
observed from the fed batch culture. Thus we assumed that little metabolism variation 
occurs with slight changes in conditions, the kinetic pattern should remain relatively 
unchanged in describing the cell culture bioprocess at reasonable extended time 
durations and different TS strategies [220]. This assumption will hold true when the 
two scenarios exhibit the same complete integral patterns from cell growth to cell death 
and therapeutic protein expression. It allows us to employ short duration (≤ 8 days) cell 
culture experiments starting from a high seeding density to approximate TS strategies 
of a full period (14 days) cell culture starting from a normal density.   
The objective of this chapter is to develop an efficient method to understand the 
temperature effect on CHO cell culture and provide a systematic strategy to develop TS 
strategies with short duration experiment for high therapeutic protein productivity via 
kinetic modeling. It aims at reducing the bioprocess development time, cost and 




3.3.1. Experiments and materials  
3.3.1.1.Cell line and cell culture 
CHO cell line A (CHO-A) was cultured in 250-ml shake flasks with 80-ml initial 
working volume and proprietary chemically defined basal media for monoclonal 
antibody production. Shake flasks were initiated with a 10 × 10P6P cells/mL inoculation 
density and cultured at constant temperatures of 32, 33, 34, 35 and 36.5 °C for 8 days. 
Meanwhile, a 0.6 × 10P6P cells/mL inoculation density was cultured at 6 different TS 
strategies for 14 days. Shaking rate and COR2 Rwere controlled at 150 rpm and at 6% 
saturation, respectively. Daily feeding started when cells reached an appropriate VCD. 
Additional glucose was supplied to maintain a proprietary concentration range [221]. 
CHO cell line B (CHO-B) was cultured in 5-L Sartorius glass bioreactors with 
Finesse control systems at 3.5 L initial working volume and proprietary chemically 
defined basal media. Experiments were initiated with a 0.6 × 10P6P cells/mL inoculation 
density at constant culture temperatures of 33, 34, 35, 36.5, 37.5, and 38.5 °C for 4 days. 
Agitation was fixed at 240 rpm, and the pH and DO were controlled at pH 7.1 and 50% 
saturation, respectively. 
To study the temperature effect on quality attributes, CHO-B was also cultured in 
2-day batch shake flasks with shaking rate at 150 rpm and incubator COR2R was 
maintained at 6% saturation. A high inoculation density of 10 × 10P6P cells/mL was 
applied at constant temperatures of 33, 34, 35, 36.5, 37.5, and 38.5 °C.  
All the above experiments were conducted in duplicates. 
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3.3.1.2.Cell culture assays 
VCD and cell viability were quantified off-line using a Vi-CELL XR automatic cell 
counter (Beckman Coulter). Glucose, glutamine, glutamate, lactate, and ammonia were 
quantified with a CEDEX Bio HT analyzer (Roche). A Protein A HPLC method was 
used to measure protein titer [221]. The highest protein titer was set as 100 % 
normalized titer in this study. For bioreactor samples, off-line pH, pCOR2R and pOR2R were 
detected using a Bioprofile pHOx analyzer (Nova Biomedical). The measured valued 
were larger than 3 × noise signal and reported less than 5 % difference in the duplicated 
experiments. 
3.3.1.3.Protein quality attribute assays 
Size exclusion chromatography (SEC) was performed using a Tosoh TSK 
G3000SWRxlR column, 7.8 cm × 30 cm × 5 μm, with an isocratic gradient monitored at 
280 nm on a Waters Alliance HPLC system (Milford, MA) equipped with a temperature 
controlled autosampler and Waters 2996 PDA detector.    
Charge Variants were assayed by Imaged Capillary Isoelectric Focusing (iCIEF), 
which was performed on a Protein Simple iCE3 instrument with an Alcott 720 NV 
autosampler (San Jose, CA).  Samples were mixed with appropriate pI markers, 
ampholytes, and urea and injected into a fluorocarbon coated capillary cartridge. A high 
voltage was applied and the charged variants migrated to their respective pI.  A UV 
camera captured the image at 280 nm.  The main peak was identified and the peaks 
that migrated into the acidic range and basic range were summed, quantitated, and 
reported as relative percent area. 
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N-Glycans analysis was performed using a commercially available kit from 
Prozyme, GlykoPrep® Rapid N-Glycan Preparation with 2-AB (Hayward, CA).  The 
free oligosaccharides were profiled using an Acquity UPLC Glycan BEH Amide, 130 
Å, 1.7 µm × 2.1 mm × 10 mm column (Milford, MA) on a Waters Acquity H-Class 
system (Milford, MA) equipped with a temperature controlled autosampler and 
fluorescence detector.  
3.3.2. Model Development 
Intracellular metabolism involves hundreds of chemicals and enzymatic reactions, 
many of which are not mechanistically understood [214, 222]. It is therefore not trivial 
to take all these reactions into consideration. Thus, an unstructured kinetic approach 
will be used to focus on nutrients, such as carbohydrates and amino acids, which 
contribute to biomass accumulation, and toxic metabolites that disturb the desired 
metabolic pathways. In this study, glucose, glutamine and glutamate were regarded as 
the representative nutrients, while lactate and ammonia were regarded as the 
representative toxic metabolites [96]. Thus, Monod based models including the main 
influential detected substrates and metabolites are applied to describe cell growth [111, 
223]. 


































iµ  (3.1-c) 
57 
 
Where, rRXR is the cell growth rate; μRGR is the specific growth rate; μRdR is the specific death 
rate; μRmaxR is the maximum specific cell growth rate; kRdR is the maximum specific cell 
death rate; X is the viable cell density (VCD), S is the concentration of the limiting 
substrate, P is the concentration of toxic metabolites; KIRSR, KIRPR, KDRSR and KDRPR are the 
saturation constants. 
Glucose is the main carbon and energy source, following the kinetic process 













µ  (3.2-a) 






 indicates the glucose consumption associated with cell growth; 
aRGlc Rdenotes the glucose consumption to maintain cell viability. Equation (3.2-a) works 
for the batch mode. 
Considering the intermittent feeding of glucose during a fed-batch mode, an integral 

























µ  (3.2-b) 








 indicates the total glucose added into the bioreactor. 
Though glutamine and glutamate are included in the media, they can also be 
generated from other substrates catalyzed by different enzymes, and then entered into 
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= ∑ µ  (3.4-a) 
Where the subscript RGln RandR GluR denote glutamine or glutamate, respectively; CRiR and CRjR 
are the i-th chemical that will generate glutamine or glutamate; rRGln Rand rRGluR are the 
glutamine and glutamate concentration change rates; YFRGlnR and YFRGlcR are glutamine and 










 indicate the glutamine and 
glutamate consumption associated with cell growth; aRGln RandR RaRGluR denote the glutamine 
and glutamate consumption to maintain cell viability; k is rate constant and K is 
saturation number in Michaelis-Menten model. 
With a well-developed chemically defined medium, there are typically sufficient 
nutrients to supply glutamine and glutamate. Thus, their generation can be regarded 






min=+∑  (3.5) 
Where, bRamino Ris a constant. 




























µ  (3.4-b) 
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Where dRGlnR and dRGluR are constants that can be either negative or non-negative. Equations 
(3.3-b) and (3.4-b) work for the batch mode. 
Similarly as glucose, when taking consideration of the daily feed of glutamine and 
glutamate during a fed-batch mode, an integral formation of equations (3.3-b) and (3.4-

























































Where, CRGln-iR and CRGlu-iR are the concentrations of glutamine and glutamate 














 indicate the total 
glutamine and glutamate added. 
As known traceable metabolites, lactate and ammonia have known effects on cells 
[28, 224]. They are generated from the central metabolism to support cell growth and 
maintain cell viability, while being consumed during cell culturing [28, 31, 224, 225]. 































][µ  (3.7) 
Where, rRLac Rand rRAmmR are the lactate and ammonia concentration change rates; a and b 
indicate the metabolite produced to maintain cell survival and associated with cell 
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growth, respectively. The metabolites can be consumed during the cell culture, 
catalyzed by enzymes such as lactate dehydrogenase or transaminases. 
To characterize the therapeutic protein production process, various substrates and 
toxic metabolites should be considered [22, 28, 226]. Organized in a comprehensive 
Michaelis-Menten structure, the kinetic equation can be expressed as [114] 



















Where QRTPR is the specific therapeutic protein production rate; KP is the maximum 
specific protein production rate; KRSR and KRPR are saturation constants. 
 
3.4.Results and Discussion 
3.4.1. Variables and constants from modeling 
Integral cell culture kinetic information can be extracted from the 8-day high 
seeding density fed-batch experiments, including cell growth and death, metabolites 
concentration change, and therapeutic protein production.  
Though KI, KD, and K denoting the enzyme binding affinities should theoretically 
respond to temperature change, our preliminary investigation using the equations (3.1) 
– (3.8) revealed that these parameters kept relatively steady (<10 % variation) within 
the temperature range studied. Therefore, the KI, KD, and K values were considered 
approximately constant in this study. This provided an intuitional comparison of μRdR, YF, 
k and KP values to describe the temperature effect on cell growth, cell metabolism and 
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protein productivity. Glucose was not a limiting substrate indicated by a small 
calculated KIRGlcR value (~10P-3Pg/L). This agrees with the feeding strategy of sufficient 
glucose supplement. 
The on-line temperature measurement indicated that it took less than 15 minutes to 
reach the shifted temperature in a 5-L bioreactor. Thus, sudden temperature shifts were 
assumed for this study. 
3.4.1.1.CHO-A 
At a high seeding density, complete mammalian cell culture patterns can be 
observed within 8-days (Fig. 3-1). Accelerated cell growth and death rates were 
associated with increased temperature (Table 3-1), as indicated by 52TμRmax R(Fig. 3-2 A, 
Table 3-1) and kRdR52T. This observation supports applying an appropriately high 
temperature for cell growth and subsequently a TS down to prolong cell viability when 
VCD was high. Though at 36.5 ºC 52TCHO-A exhibited the highest growth rate in the 
exponential phase, it reached the highest peak VCD at 35 52TºC52T. The μRmaxR indicated that 
at these two temperatures, CHO-A growth ability was similar (Fig. 3-2 A). The 



































































































































Figure 3-1. CHO-A profiles of VCD (A) and metabolites (B: glucose, C: glutamine, D: 
glutamate, E: lactate, F: normalized therapeutic protein titer. The points represent 
experimental data and the lines represent the simulation results. Calculated kinetic 


















































Table 3-1. Key kinetic parameters of CHO-A 
Temperature °C 32 33 34 35 36.5 Ref.[96, 209, 
227, 228] 
Cell Growth μRmax R(hP-1P) 0.36 0.44 0.52 0.90 0.93 0.26 – 1.2 
kRd R(dayP-1P) 0.05 0.14 0.23 0.26 0.49  
Protein KP (g·dayP-1P·10P-9PcellsP-1P) 0.48 0.46 0.44 0.40 0.37 0.3 – 0.64 
Glutamine aRGln R(mmol·10P-10PcellsP-1P·hP-1P)  -3.6 -4.2 -4.9 -4.1 -5.7  
YFRGlnR (10P6Pcells·mmolP-1P)  37 52 86 104 183  
Glutamate aRGlu R(mmol·10P-11P·cellsP-1P·hP-1P)  3.9 3.6 3.8 10 7.3  
YFRGlu R(10P6Pcells·mmolP-1P)  24 28 68 146 139  
Glucose aRGlc R(g·10P-13PcellsP-1P·h-1) 5.2 6.5 7.6 13 16  
YFRGlcR (10P9Pcells·gP-1P)  3.0 2.7 2.1 1.7 1.6 2.0 – 3.4 
Lactate aRLac R(g·10P-12PcellsP-1P·hP-1P) 10 8.1 5.5 4.6 4.1  
bRLac R(g·10P-9PcellsP-1P)  0.83 1.2 1.6 2.3 5.6  
kRLacR (g·10P-11PcellsP-1P·hP-1P)  0.87 1.1 1.1 1.8 2.6  
Ammonia aRAmm R(mmol·10P-9P·cellsP-1P·hP-1P) 0.53 1.2 1.7 6.7 9.6  
bRAmm R(mmol·10P-10P·cellsP-1P) 2.9 2.7 3.2 2.2 1.8  
kRAmm R(mmol·10P-9PcellsP-1P·hP-1P) 0.93 1.8 3.4 6.0 18.7  















































 A trend of enhanced glutamine and glutamate utilization efficiency for cell growth 
was observed from the ascending YFRGlnR and YFRGluR values with increasing temperature. 
Contrarily, descending YFRGlcR and ascending aRGlcR referred to lower glucose utilization 
efficiency with increasing temperature. This indicates that an appropriate hypothermia 
temperature shift with the studied temperature range may enhance the glucose 
utilization but may not favor the amino acids utilization efficiency for CHO-A.  
Lactate metabolism was also sensitive to temperature. With increasing temperature, 
higher kRLacR and bRLacR, and lower aRLacR were obtained, implying that higher temperature 
accelerated lactate consumption but had less effect on lactate production. This 
explained the earlier lactate metabolism shift and lower lactate peak value at higher 
temperatures.  
Though 52Tthe highest therapeutic protein titer was observed at52T 34 ºC52T, the productivity 
(KP) was negatively correlated with temperature increase (Fig. 3-1), potentially due to 
the maintenance of active central metabolism, cell respiration and mitochondrial 
biogenesis [211]. Fig. 3-2 exhibited that μRGR and KP had opposite relevance with 
temperature. Because protein production was associated with both integral cell density 
and specific protein productivity, a TS strategy provides good balance of μRGR and KP 
were required to reach a high harvest therapeutic protein titer. 
3.4.1.2.CHO-B 
A 4-day batch cell culture behavior is shown in Fig. 3-3. Within the studied 
temperature range, µRmaxR doubled from 33 to 34 ºC52T and continued to increase slightly 
with ascending temperature from 52T3452T to 38 52TºC52T. 52TCell death rate ( dk ) however increased 
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with ascending temperature. This indicates that a moderate temperature should be 
applied for fast VCD expansion. In contrast to CHO-A, CHO-B exhibited optimum 
temperatures at 35 and 36.5 ºC for high glucose (YFRGlcR) and glutamate (YFRGluR) 
utilization. From 33 to 38.5 ºC52T, 52TaRLacR and kRLacR were doubled while aRAmmR and kRAmmR 
exhibited little change (Table 3-2). This indicates that its lactate metabolism was more 
sensitive to temperature than ammonia. A TS strategy may have more effect on lactate 





































































































































Fig, 3-3. CHO-B profiles of VCD (A) and metabolites (B: glucose, C: glutamine, D: 
glutamate, E: lactate, F: ammonia. The points represent experimental data and the lines 




















































Table 3-2. Key kinetic parameters of CHO-B 
Temperature °C 33 34 35 36.5 37.5 38.5 
Cell Growth μRmax R(hP-1P) 0.059 0.116 0.121 0.126 0.128 0.120 
kRd R(dayP-1P) 0.048 0.065 0.084 0.13 0.13 0.14 
Glutamate YFRGlu 
R(10P6Pcells·mmolP-1P) 
15 29 56 55 25 14 




4.0 5.0 5.0 7.7 8.0 8.1 
















7.9 8.5 8.5 8.5 8.5 8.5 
 
3.4.2. Temperature shift strategy prediction 
3.4.2.1.Titer prediction for CHO-A 
Using kinetic parameters determined in the previous section, the models (3.1) to 
(3.8) are used to compute the VCD and therapeutic protein profiles of CHO-A with a 
normal seeding density of 0.6×10P6P cells/ml at different TS strategies. While a 
continuous temperature shift condition may reports the highest titer, a current industry 
applicable TS strategy for manufacturing is one- or two-step shift. Table 3-3 listed the 
predicted titer on harvest day (day 14) based on 31 different TS strategies via kinetic 
models (3.1) - (3.8). These designed TS strategies include the temperature shift occurs 
on different days, via different steps, and to different temperatures, which should 
represent the typical TS strategies that could be applied for bioprocess development. 6 
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TS strategies were validated by experiments, which showed less than 3 % titer 
difference between the predicted and validated values. From the table, a day 10 shift 
from 36.5°C to 33°C reported the highest titer, which was set as 100 % normalized titer 
in this study. 
 

















1 NA Pe 89.14   
2 6 32 82.07   
3 33 87.89 90.24  
4 34 92.29 92.32  
5 35 92.41   
6 8 32 87.34   
7 33 95.14 96.82  
8 34 97.77 97.83 * 
9 35 97.98  * 
10 10 32 92.11   
11 33 100.00  * 
12 34 98.53  * 
13 35 93.82   
14 Pf 6 8 35 32 87.18   
15 33 94.89   
16 34 97.43  * 
17 34 32 87.27   
18 33 94.46 94.19  
19 33 32 83.27   
20 6 10 35 32 87.67   
21 33 95.17   
22 34 97.64  * 
23 34 32 92.75   
24 33 94.80   
25 33 32 86.97   
26 8 10 35 32 88.13   
27 33 95.41   
28 34 97.86  * 
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29 34 32 98.10  * 
30 33 95.14 95.11  
31 33 32 90.64   
P
a
P The temperature was kept at 36.5 °C before the temperature shift. 
P
b
P Predicted titer on harvest day (day 14). 
P
c
P Average titer measured in validation experiment, the experiment was operated in duplication. 
P
d
P The TS strategy candidates for high titer was marked with *. The qualified TS strategies was 
shortlisted based on its normalized predicted titer ≥ 97 % 
P
e
P NA means the temperature was set to be constant at 36.5 °C without TS. 
P
f
P The temperature shift occurred twice, first on day 6 to 35°C, and then on day 8 to 32°C. The same 
‘twice temperature shift’ strategies were applied from No. 14 to No. 31 except the shifting dates and 
temperatures vary. 
 
Considering the 3 % modeling deviation, the top productivity TS strategies can be 
screened based on the normalized predicted titer ≥ 97 % in Table 3. Thus, 8 TS strategies 
were shortlisted as candidates for high titer, while most of them includes a temperature 
shift to 33 ºC or 34 ºC. This means 33 ºC and 34 ºC ensured a good balance of cell 
growth (μRGR) and specific protein productivity (QRTPR), which agrees with the trends in 
Fig. 3-2. Instead of testing all the 31 TS strategies, this modeling method allows to 
narrow the candidate high productivity TS strategies to 8. It potentially saves 74 % of 








Fig. 3-4. VCD (A) and normalized protein (B) profiles and model validation of CHO-
A computed at different TS strategies with an initial VCD of 0.6 × 10P6P cells/mL and 
temperature shifted from 36.5 °C to 33 or 34 °C on different days and steps. The lines 
denote to the computing results and the points represent the experimental data for model 
validation. 
Fig. 3-4 showed that not only final titer but also the VCD and protein profiles were 
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that the shifting time of day 6 or day 8 had more impact than temperature choice of 33 
ºC or 34 ºC on VCD profile. A later shift supported a higher peak VCD. Meanwhile, 
both temperature and shift time were important for the protein titer. A later shift and 
higher shift temperature favored higher titer. However, a multi-step TS strategy that 
involved shifting to 34 ºC first and then to 33 ºC after two days, was also capable of 
reaching a similar level of protein titer as a single-step temperature shift strategy to 34 
ºC, which was a comprehensive outcome of cell growth, death and protein expression. 
Since temperature may have an impact on therapeutic protein quality, the listed 
multi-step TS strategies in Table 3-3 and Fig. 3-4 provide a choice to reach a similar 
protein titer at various temperatures, which may be employed to optimize the protein 
quality. Kinetic modeling provides an efficient means to predict the VCD and protein 
profiles for screening an optimal TS strategy, instead of testing all the possible TS 
strategies by experiments. 
3.4.2.2.VCD prediction for CHO-B 
For some CHO cell lines, it may hold the truth that that the KP are relatively inert 
with temperature. Thus, protein titer may heavily rely on VCD. Under this assumption, 
even shorter cell culture can be sufficient to contain the cell growth kinetic information, 
and further be applied as to predict the VCD profiles for rapid TS strategy screening. 
In this study, 4-day batch experiments of model cell line CHO-B at consistent 
temperatures were applied to predict the cell growth performance up to 10 days at 









Fig. 3-5. VCD profiles prediction and validation of CHO-B at different TS strategies 
with an initial VCD of 0.6 × 10P6P cells/mL: TS from 36.5 °C to 35, 34 and 33 °C 
respectively on day 4 (A); TS from 36.5 °C to 33 °C on day 4, day 6 and day 8, 
respectively (B). M represents a multiple temperature shifting strategy: TS from 36.5 
°C to 35 °C on day 4, then to 34 °C on day 6, and finally to 33°C on day 8. The lines 
denote the computational prediction results and the points represent the experimental 
data for validation. 
 









































different TS strategies in a fed-batch mode, which validated by the experimental results. 
It indicated that higher shifting temperature and late TS time were beneficial for 
biomass accumulation in this case. Specifically, a multi-step TS starting from day 4 was 
also capable of achieving a similar VCD as TS at day 8, which indicated that less 
disturbance would apply stress on cell growth by gradual TS [210].  
3.4.3. Therapeutic protein quality attributes 
Temperature affects not only biomass accumulation and therapeutic protein 
productivity, but also protein quality attributes [210, 211], including high molecular 
weight (HMW) [229], charge variants [230, 231], and N-linked glycosylation [72, 232]. 
Instead of detecting after a full period cell culture, a short duration of 2-day batch run 
of CHO-B with a high seeding density of 10×10P6P cells/ml was used to characterize the 
trends of temperature effect on the protein quality attributes (Fig. 3-6). After 2-day cell 
culturing, variation of quality attributes could be observed. A hypothermal operation 
favored a high percentage of front intermediate, while an appropriate megathermal 
operation reported a high Man5 percentage. Temperature below 36.5 ºC generally 
reported lower acidic peak and higher basic peak than that above 36.5 ºC. Meanwhile 
























































Fig. 3-6. Impact of cell culture temperature on protein quality attributes including 
HMW (A), charge variant (B & C), and Man5 (D). CHO cell line B cultured in a 125-


































The temperature effect on CHO cell bioprocess from 32 to 36.5 °C and from 33 to 
38.5 °C for two CHO cell lines were systematically studied via kinetic modeling. These 
two CHO cell lines exhibited different responses to temperature change on the aspects 
of cell growth, therapeutic protein productivity, and nutrients and metabolites 
metabolism.  
Kinetic modeling was applied for rapid TS strategy screening and prediction. A 
series of 8-day CHO cell culture with high seeding density of 10×10P6P cells/ml at 
different constant temperatures were applied to predict 14-day CHO cell culture 
processes with normal seeding density of 0.6×10P6P cells/ml at different TS strategies. 
Meanwhile, a series of 4-day batch CHO cell culture which contained sufficient 
exponential phase kinetic information, was applied to predict the bioprocesses to an 
extended period of 10 days in a fed-batch mode. Therapeutic protein quality attributes 
in short duration experiments exhibited the trends of those in the 14-day cell culture, 
which could also be potentially applied for indicating the full-duration cell culture.  
Owing to the short time needed for each temperature shift, sudden temperature shift 
or step changes were applied in the kinetic modeling study. However, it may take hours 
to reach the down shifting temperature in the manufacturing scale bioreactor (2,000 – 
25,000 L). Step change in temperature may not be applicable. This study was performed 
with two model CHO cell lines, the general methodology developed here is applicable 
to other therapeutic protein production by mammalian cells with reduced process 
development time and financial investment.For a better understanding of cell culture, 
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an insight view of the intracellular enzymes is beneficial. The next chapter will provide 







A Mechanistic Kinetic Description of Lactate Dehydrogenase Elucidating Cancer 
Diagnosis and Inhibitor Evaluation 
4.1. Abstract 
As a key enzyme for glycolysis, lactate dehydrogenase (LDH) remains as a topic of 
great interest in cancer study. Though a number of kinetic models have been applied to 
describe the dynamic behavior of LDH, few can reflect its actual mechanism, making 
it difficult to explain the observed substrate and competitor inhibitions at a wide 
substrate concentration range. A novel mechanistic kinetic model is developed based 
on the enzymatic processes and the interactive properties of LDH. Better kinetic 
simulation as well as new enzyme interactivity information and kinetic properties 
extracted from published articles via the novel model was presented. Case studies were 
presented to a comprehensive understanding of the effect of temperature, substrate, and 
inhibitor on LDH kinetic activities for promising application in cancer diagnosis, 
inhibitor evaluation and adequate drug dosage prediction.   
Keywords: cancer diagnosis; inhibitor evaluation; kinetic model; lactate 





Lactate dehydrogenase (LDH) is an essential enzyme in nearly all living cells [233, 
234], which catalyzes the mutual transformation between pyruvate and lactate, 
associated with nicotinamide adenine dinucleotide compounds (NADH and NADP+P) 
interconversion [235] (Fig. 4-1). Because cancer cells heavily rely on aerobic glycolysis 
to support their growth, LDH comes to be an emerging anticancer target for cancer 
diagnosis and treatment [236]. Besides the enzyme level and catalytic mechanism, its 
kinetic properties have also attracted wide interests [91, 237]. From 1997 to 2016, 
approximately 1625 publications are found as LDH kinetic related, based on our query 
and manual filtration on a peer-reviewed literature database named as ScopusP®P. 
 
 




To inhibit the glycolysis within cancer cells, hundreds of small molecules are under 
study to reduce LDH activity. One type of inhibitor candidates are molecules that have 
similar chemical structures as pyruvate and are able to competitively associate on the 
substrate domain. Oxamate derivatives (Fig. 4-2), for example, are one type of model 
inhibitors [238]. These molecules are able to seize the available substrate-binding sites 
and further inhibit substrate binding and reactivity. Meanwhile, tumor cells respond 
differently from normal cells to temperature changes [239]. Therefore, a universal 
method to quantitatively describe the kinetic properties of LDH and evaluate the effect 








As a tetramer existing in most physiological environments [241, 242], one LDH 
molecule has four subdomains, and thus, is able to bind up to four substrate molecules 
and four coenzyme molecules. The binding of one or more substrate and coenzyme 
molecules regulates the oligomeric enzyme protein folding, leading to dynamic enzyme 
activity change. Thus, LDH is an interactive enzyme known to possess allosteric 
properties [89, 243]. 
Several kinetic models have been applied to describe LDH performance. However, 
few are able to elucidate the enzymatic process mechanistically. Known models include 
Michaelis-Menten (M-M) Equation, Hill Equation [94, 97, 103, 244], Binding Model 
of Alberty [105, 245], Monod-Wyman-Changeux (MWC) Model [89, 90], and 
empirical models derived from software of JMP [105]. The deficiency of these models 
is mainly the failure in taking a comprehensive consideration of the complex interactive 
processes and allosteric properties of the oligomeric enzyme.  
The objective of this chapter is to develop a mechanistic kinetic model based on the 
interactive enzyme properties that is capable of describing temperature, substrate and 
inhibitor effect. It aims at better kinetic simulation of the enzymatic process, a 
comprehensive understanding of the enzyme behavior in complex conditions, as well 




Due to the interactive nature, an oligomeric enzyme exhibits unique kinetic 
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properties at each successive binding. Thus, a mechanistic kinetic model needs to take 
all the information of enzyme interactive regulations caused by sequential coenzyme, 
substrate, and inhibitor binding into consideration. In order to better understand the 
enzyme kinetic properties and simplify the mathematic formula, this study focusses on 
the initial reaction rates. An isoenzyme consisted of identical subunits is used as the 
modeling example. Therefore, the binding and dissociation processes can be expressed 
as  
ERnRSRi-1R + S → ERnRSRiR, rR+niR = (n-i+1) kRni+R[ERnRSRi-1R][S] [4.1-a] 
ERnRSRiR → ERnRSRi-1R + S, rR-niR = ikRni-R[ERnRSRiR]  [4.1-b] 
Where, n is the total number of available binding sites of the oligomeric enzyme ERnR, S 
denotes for the binding substrate, ERnRSRiR denotes for one enzyme molecule bound with i 
substrate molecules, kRni+R is the binding rate constant for substrate molecule on each of 
the (n-i+1) vacant sites, and kRni-R is the dissociation of a substrate molecule from each of 
the i bound substrate molecules. 
It is assumed that the binding is much faster than the reaction. Thus, thermodynamic 


























































































α  [4.3-c] 










































































































The overall catalytic reaction rate for an oligomeric enzyme with n-reactive binding 








1 ][][ β  [4.6] 
Where, β is the coefficient indicating the interactive effect on reactivity. 
 
4.4.Results 
4.4.1. LDH Saturated with coenzyme 
LDH, as an interactive tetrameric enzyme, follows the general mechanistic kinetic 
principles expressed above. In studies conducted to examine the substrate (pyruvate or 
lactate) effect on LDH kinetic activities, an excess of coenzyme (NADP+P or NADH) is 
generally added to saturate and fully activate the enzyme [246, 247]. Based on the 

































β  [4.7] 
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Fig. 4-3. Sequential substrate binding and reaction processes on LDH at the coenzyme 
saturation condition. 
 
While it is conceivable to have the affinities vary extensively during the subsequent 
binding, there could be a pattern of affinity change. In this case, the cooperative effect 
is significantly simplified. If we let 
 αααα === 321  [4.9-a] 
 ββββ === 321  [4.9-b] 
The model now signifies that the successive binding approaches the same incremental 
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proportional affinity change. 






































=  [4.11] 
Equation [4.11] is the familiar M-M formula. Reaching this result after applying the 
aforementioned conditions explains how the M-M model can approximately simulate 
the kinetic process at low substrate concentrations. Equation [4.10] is in agreement with 
the conventional M-M model but is applicable outside of the limited condition. 
Generally, α < 1 is favorable for subsequent substrate binding; β > 1 indicates that 
subsequent binding accelerates the on-site reaction. 
4.4.2. LDH competitive effector binding model 
Inhibitors, such as oxamate derived molecules (Fig. 4-2), can seize the LDH 
substrate binding sites (Fig. 4-4) and reduce the enzyme activity. Therefore, at the 








































        ( )41 ≤≤ i  [4.13-b] 















































ij SEIE  [4.14] 
Where, S and I are the substrate and inhibitor, respectively; k is the reaction rate constant 
of the first binding substrate without inhibitor; K is the saturation coefficient of the first 
binding of substrate (KRSR) or inhibitor (KRIR); α, β and γ are the interactive coefficients. 
The subscripts i and j associated with I and S indicate the number of substrate and 
inhibitor molecules bound to the enzyme complex, respectively; α and γ indicate the 
interactive binding effect on subsequent substrate and inhibitor, respectively; β 
indicates the interactive effect on reactivity. 
 
 
Fig. 4-4. Typical substrate and inhibitor binding and reaction processes. (
)4,,1 ≤+≤ jiji . S, P and I are the substrate, product, and competitive effector, 




Following a similar assumption as equation [4.9-a] and [4.9-b], we let  
 αα =nm,           )31( ≤+≤ nm  [4.15-a] 
 Sm ββ =,0                  )31( ≤≤ m  [4.15-b] 
 ISmn ββ =,          )3,1( ≤+≤ mnn  [4.15-c] 
 γγ =mn,              )31( ≤+≤ nm  [4.15-d] 
Where, subscript RSR indicates no inhibitor bound on the enzyme molecule and the 
interactive effect is only caused by subsequent substrate binding; subscript RISR indicates 
that the interactive effect is caused by both inhibitor and substrate molecules bound on 
the enzyme complex. 























































































































































































I  [4.17] 
Specifically, at a low inhibitor and substrate level, higher order items are negligible, 







































Equation [4.18] is mathematically similar to the binding model of Alberty [105, 114, 
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245]. This explains the applicability of the conventional binding model of Alberty for 
LDH, under the low substrate and inhibitor condition. 
At low inhibitor and moderate substrate concentrations, [I] items are negligible, 




































Equation [4.19] is identical to equation [10], which demonstrates that equation [4.16] 
is a more general equation for the initial rate of LDH catalyzed reactions. 
 
4.5.Discussion  
4.5.1. Substrate concentration and temperature effects 
To study the substrate concentration and temperature effects, human LDH type 1 
(hLDH-1) was used as an example. Three data sets were selected from two publications, 
reported by Vesell [248] and Gubernieva [249], for the initial catalytic rates of hLDH-
1 in converting pyruvate to lactate. The isoenzymes were extracted from human heart, 
psoas muscle, liver, or pancreas tissue within 12 hours of death. The experiment was 
controlled at 20, 25, and 37 °C, respectively. The isoenzymes were pre-saturated by 
NADH before initial rates were measured. The initial reaction rates were measured with 
different levels of pyruvate by a spectrometer at 340 nm. The data were selected from 
these publications and reanalyzed via equation [4.10]. 
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Enzyme hLDH-1 exhibited sensitive responses to temperature (Fig. 4-5). This 
isoenzyme reported significant substrate inhibition when pyruvate concentration is 
higher than 1 mM. The calculated β < 1 indicates that the subsequent substrate binding 
reduced the reactivity. Thus, a higher ratio of [ESRiR]/E (i >1) could lower LDH activity 
at a high pyruvate concentration. A smaller α indicates enhanced binding on subsequent 
sites. Therefore, at 37 °C, reporting small α and β values, could be the preferable choice 









Temp. (°C) kE/rRmax α K (M) β αK (M) 
20 1.6 2.9 0.52 0.062 1.5 
25 1.3 14 0.73 0.047 10 
37 1.5 3.0 1.1 0.034 3.4 
Fig. 4-5. (A) Temperature effect on the activity of hLDH-1 with data taken from 
publications [248, 249]; (B) Van’t Hoff Equation simulation of hLDH-1 K values. 
hLDH-1 kinetic parameters at different reaction conditions are listed in the table. The 





































Equation [4.10] can be applied to predict the substrate concentration when the 






       [4.20] 
the theoretical substrate concentrations to reach the peak activity can be calculated as 
0.4, 1.1 and 0.7 mM at 20, 25, and 37 °C, respectively, which agree with observed 
values in the experiments (Fig. 4-5). 
Besides explaining the interactive properties and simulating the kinetic 
observations, equation [4.10] helped to reach a comprehensive understanding of 
temperature on pyruvate binding, which was not reported elsewhere. For a robust 
enzyme, if its structure is not sensitive to temperature changes, the binding saturation 















































Where, ΔERaR is the activation energy difference between the backward and forward 
reaction or the heat of binding, R is the ideal gas constant, T is temperature (K); KR0 Ris a 
constant. 
The approximately linear regression indicates that hLDH-1 is a relatively robust 
enzyme within the studied temperature range of 20 ~ 37 °C (Fig. 4-5 B). The calculated 
ΔERaR was 31.5 kJ/mol. The relatively integral enzyme structure indicates that the hLDH-
1 subunits are relatively rigid. The initial binding affinity at other temperatures within 
the studied temperature range can thus be predicted via this model. 
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4.5.2. Cancer diagnosis 
Cancer is one of the global leading causes of death [251]. Abnormal LDH kinetic 
properties and concentrations have been observed for tumor cells in comparison to 
normal cells [252, 253]. Currently, LDH is a useful marker for diagnosing cancer due 
to its role in the final step of the aerobic glycolysis [254]. 
One set of data from experiments conducted by Talaiezadeh. [91] was reprocessed 
with current model to provide insight on its behavior. In [91], LDH isoenzymes were 
extracted and purified from normal and malignant human breast tissues. The enzymes 
were dissolved in a pH 8 buffer solution. The experiments were conducted similarly to 
those used in section 4.5.1. 
Fig. 4-6 showed that LDH from tumor human breast cells (T-hLDH) exhibited an 
enhanced catalytic activity as compared to the isoenzyme from normal human breast 
cells (N-hLDH). This is confirmed by the k values of T-LDH which was five-fold larger 
than that of N-LDH. The small α values of both LDH isoenzymes indicate that 
subsequent substrate binding was favored by the cooperative effect. However, this 
cooperative effect inhibited the enzymatic activity, indicated by the β < 1.  The smaller 
β value of T-LDH than that of N-LDH indicates that T-LDH is a more substrate 
sensitive isoenzyme than N-LDH. Since dynamic intracellular pyruvate concentration 
always remains low in mammalian cells [31, 255], a quantitative analysis of k/K showed 
that the reaction within tumor cells could be potentially two-fold of that in normal cells 
at very low pyruvate concentrations (Fig. 4-6). This explains the abnormal high 






Source k (mU/mg 
protein) 
α K (mM) β k/K (U/M·mg 
protein) 
Normal human cells 4.7 0.056 13 0.10 0.36 
Tumor human cells 27 0.050 37 0 0.73 
Fig. 4-6. The initial rates of LDH from tumor human breast cells (T) and normal human 
breast cells (N) vary with substrate concentrations in conversion of pyruvate to lactate; 
The data were taken from the publication [91]; Kinetic parameters of different LDH 
isoenzymes are listed in the table. The dots denote the experimental data and the lines 

























While N-LDH still retained a reduced activity (β = 0.1), T-LDH became inactive (β 
= 0) when more than one substrate molecule was bound on it. Therefore, molecules 
which have similar structures as pyruvate may strongly inhibit T-LDH activity, while 
have lesser effects on N-LDH. 
4.5.3. Inhibitor evaluation and dosage prediction 
Because most tumor cells heavily rely on an enhanced glycolysis activity in 
converting glucose to lactate to maintain metabolic requirements [258], studies have 
been focused on those inhibitors which can significantly reduce LDH activity for 
potential cancer treatment [259, 260]. 
The experiment data were reported by Rodriguez-Paez [240]. Initial rates of 
pyruvate conversion to lactate catalyzed by mouse LDH were measured with different 
additions of N-propyl oxamate. The experiments were conducted similarly as the case 
studies utilized in the previous sections.  
The data were reprocessed via equation [4.16] and shown in Fig. 4-7. One set of 
parameters was able to elucidate the kinetics at various inhibitor and substrate 
conditions. Thus, quantitative standards can be built up to characterize the effect of an 
inhibitor regardless of its dosage. Typically, small γ, KRIR, and βRISR values, which indicate 
high binding competitiveness and reduced reactivity, are preferred for a high 
performance inhibitor. In this case study, the calculated α, γ > 1 indicates that both 
pyruvate and N-propyl oxamate are retarding ligands, inhibiting subsequent substrate 
and inhibitor binding on the enzyme. N-propyl Oxamate exhibited lower binding 
affinity than pyruvate at low concentrations (KRIR > KRSR), while its binding affinity 
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exceeded pyruvate at high concentrations (γKRI R< αKRSR). Substrate inhibition was not 
observed from this experiment (βRSR = 1.0). However, when both substrate and inhibitor 
molecules were bound, the LDH activity could be reduced by the substrate-inhibitor 
cooperation (βRISR = 0.7). Therefore, oxamate inhibited LDH activity not only by seizing 
the substrate binding domains but also by reducing the reactivity. This makes N-propyl 









kE/rRmax α γ βRS βRIS KRSR (mM) KRIR (mM) αKRSR (mM) γKRIR (mM) 
30 38 7.3 1.0 0.70 2.5 ×10P-3 3.6 ×10P-3 0.095 0.026 
Fig. 4-7. (A) Inhibition of N-propyl oxamate on LDH for the conversion of pyruvate to 
lactate with experimental data taken from the publication [240]. (B) Kinetic prediction 
of N-propyl oxamate required to inhibit LDH activity at 50 % and 25 % at 0.2 mM 
pyruvate concentration. The dots denote the experimental data and the lines represent 








































Besides the mechanistic understanding of the enzyme properties, this model also 
serves for adequate inhibitor dosage study. An accurate inhibitor dosage to reach a 
target LDH activity can be predicted via this model instead of testing in the lab. For 
instance, based on the disease diagnosis study (Fig. 4-6), The enzymatic activity within 
a normal cell is 50 % of a tumor cell around the pyruvate concentration of 0.2 mM 
which is a typical level within cells [261]. Via equation [4.16], it can be calculated that 
50 μM of N-propyl oxamate can successfully halve the activity of LDH, while 192 μM 
can further halve it (Fig. 4-7 B). This provides the basis to set up adequate inhibitor or 
drug doses, avoiding any insufficient or excessive dosage. 
Overall, this model builds up uniform standards to evaluate different kinds of 
inhibitors by comparing γ, KRIR, and βRISR values. It is able to use one set of parameters to 
mechanistically evaluate the inhibitors regardless of their concentrations, instead of 
using classical M-M model to get different sets of kinetic parameters at various inhibitor 
levels. Besides, it can compute a theoretical inhibitor dosage to reach a target inhibitory 




In this chapter, a new mechanistic kinetic model was developed to explain the 
kinetic properties and dynamic behaviors of oligomeric enzymes, such as LDH, based 
on the interactive nature of enzyme-ligand bindings. The effects of temperature, 
substrate concentrations, and competitive effectors were analyzed mechanistically with 
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case studies. The kinetic information extracted from the new models provided a 
theoretical understanding of LDH, and was able to evaluate inhibitor effect with 
uniform standards and predict the kinetics at different substrate and inhibitor levels. 
This may promote further advancements in disease diagnosis, enzyme activity control, 
drug evaluation as well as adequate medication dosage. 
Based on the above two chapters, the kinetic modeling methods were built up to 
achieve the high cell culture titer and understand the enzyme properties. A next chapter 
will focus on the biologics quality control by process development, which is also a 




Monoclonal Antibody Quality Control by Process Development 
5.1. Abstract 
With the consensus that quality is always paramount in the biopharmaceutical 
industry, much attention has been paid on the quality control strategies. Process 
development is the bridge connecting the drug discovery and manufacturing, which has 
a crucial impact on the biologics quality. In this review, the process development tasks 
were briefly summarized; the critical quality attributes and quality control methods via 
process development were discussed. It aims at providing an overview picture of 
monoclonal antibody critical quality control strategies by process development based 
on the Quality by Design principle. 
 
Keywords: Quality by Design; process development; critical quality attributes 
 
Abbreviations: 
CHO, Chinese Hamster Ovary; CQA, critical quality attributes; DoE, Design of 




After a fast expansion of monoclonal antibodies (mAbs) market, both the supply 
and demand of biologics are increasing rapidly [3, 6, 262]. Being life related, mAbs 
direct impact on the clients’ health. Thus, the quality has been recognized as the most 
important aspect. Based on the Quality by Design (QbD) principle proposed by FDA, 
the quality of biologics and drugs should be well designed and developed in the pre-
clinical stage instead of measuring during the manufacturing [263]. Therefore, a good 
understanding of the impact of different processes on quality is beneficial for mAb 
quality design and control. 
Four stages were included in a typical process development project: cell line 
development, upstream process (cell culture) development, downstream process 
(purification) development and formulation development [264-266]. While cell line 
development may be excluded in some biopharmaceutical companies, it is discussed as 
one process development stage in this work. Critical quality attributes, including the 
amino acid sequences [267], N-glycan [268], charge variants [269], etc. have important 
impacts on the mAb efficacy and stability. Some of the quality attributes can be 
designed and controlled via multiple process development steps, while others can only 
be controlled at one certain unit operation. An understanding of the practical process 
development strategies for quality control can help to design a time- and cost-efficient 
manufacturing process to achieve the desired mAb quality. 
In this chapter, the tasks of different process development steps were summarized; 
the concept of Quality by Design (QbD) was introduced; the process development 
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strategies for quality control were discussed. This work aims at providing an overview 




Shown in Fig. 5-1, four process development stages are classified by their working 
tasks. The full length of a process development project may take one to three years, 
depending on the requirements of the project and the local regulations. Obviously, a 
long period of process development is beneficial to develop a high quality 
manufacturing technology, while short period is always desired by the 
biopharmaceutical companies to reduce the cost and accelerate the product 
commercialization process [267]. A practical process development strategy should be a 




Fig. 5-1. The tasks of each process development stage. 
 
5.3.1. Cell line development 
The core task of cell line development is to develop monoclonal host cell line 
candidates with stable, high titer expression of high quality mAbs [16, 270]. As the first 
stage of process development, the result of cell line development has a  sustained 
impact on the following stages. After the gene editing and vector transfer to the host 
cells, around 10,000 clones are screened to get a few high performance monoclonal cell 
line candidates [270]. They are then sent to upstream for a further screening and cell 
culture development. Series of characterization need to be conducted to ensure that the 
cell lines are free of mycoplasma and virus, as well as the therapeutic protein has the 
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correct structure and amino sequence. An early detection of titer and protein quality is 
also taken to provide hints for upstream process development. After the determination 
of top clones, the clone stability test will be done to ensure good stability of the selected 
clones. Meanwhile, the master and working cell banks are established.  
5.3.2. Upstream process development 
Upstream process development focuses on cell culture development [264]. It aims 
at developing a scale-up-able and robust process to reach high titer and high quality 
[42]. As the second process development stage, upstream usually starts with a few top 
clone candidates. At the early upstream stage, shake flasks are widely used for an 
overall understanding of the cell culture properties and a rapid approach to a suitable 
cell culture process. While at the late upstream stage, bioreactors are more commonly 
utilized to better control and accurately regulate the cell culture parameters, and then 
further scale up to the pilot production system. 
5.3.3. Downstream process development 
Downstream process development is responsible to develop a scale-up-able and 
robust process to achieve high yield, high purity and high quality products [271]. As 
the third process development step, it starts once receiving the harvest samples from 
upstream. Different chromatography and associated devices are used to capture the 
target mAb, remove impurities and control the quality attributes. Various buffers, 
columns and process parameters are optimized at this stage based on the Design of 
Experiment (DoE) principle. At current technology level, > 90 % of purification yield 
can usually be reached for each unit operation, with a total downstream yield > 60 % 
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in the industry. 
5.3.4. Formulation development 
As the last stage of process development, formulation development is to achieve a 
stable and appropriate formulation buffer to ensure the biologics are easy and safe for 
patient to take [272]. Typical formulation may contain salts, carbohydrates, amino acids, 
surfactants, etc. Compared to the other three stages, formulation development pays 
more attention to keeping the intellectual rights and developing a platform formulation. 
Fig. 5-2 provides an example of process development framework. It keeps similar 
when being scaled up to a manufacturing system. The usage and arrangement of the 
columns may vary depending on the nature of the project. Each step plays its unique 




Fig. 5-2. One typical flow chat of a typical bio-process development operation process 
from host cell obtain from cell bank to the formulation and filling. CLD: cell line 
development; UPD upstream process development; DPD, downstream process 
development; FD, formulation development. 
 
5.4. Quality by Design 
The concept of QbD can be traced back to 2003, proposed by FDA, and be further 
officially included in the FDA Process Validation Guidance in 2011[263, 273]. The 
same concept was explained in ICH section Q8 as “A systematic approach to 
development that begins with predefined objectives and emphasizes product and 
process understanding and process control, based on sound science and quality risk 
management”[274]. It means products and process characteristics are scientifically 
designed to meet specific objectives, not merely derived from empirical knowledge or 
performance of test batches[263]. Thus, a mechanistic understanding of the process 
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performance, as well as the quality attributes mechanism and effect, is indispensable to 
develop QbD based bioprocesses. Bio-process development, from the above point of 
view is no more solely engineering work. It needs a scientific understanding of the 
molecular biology, enzymology, genomics, bio-kinetics, and fluid mechanics, etc. An 
interdisciplinary education or knowledge background may be a requirement for an 
outstanding PD scientist in the near future. 
Generally, three aspects are included in the QbD concept[273, 274]:  
A). Process Development. It aims at design and develop a good process to meet the 
quality attributes requirement; 
B). Process Characterization. It targets on building up a robust and risk managed 
process; 
C). Process Validation. Its goal is to set up validated design space.  
In this chapter, our discussion is focused on (A) process development, which is the first 
and fundamental part to mechanistically design and control the quality attributes. 
 
5.5. Critical Quality Attributes Control 
A good understanding of these critical quality attributes (CQAs) and the quality 
control process development principles will be beneficial to develop an appropriate 
process for mAbs manufacturing. Table 5-1 summarized the ability of each process 
development stage or unit operation to regulate the CQAs, which will be discussed in 
this section.  
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Table 5-1. Typical critical quality attributes control strategies at different process 
development steps or unit operations. 








CLD  Cell 
Engineering 
√√ √  √ √  
 Clone 
screening 
√ √  √   
UPD  Top clone 
screening 
 √√  √   
 Medium 
optimization 




 √√ √ √√ √√  
DPD  Protein A     √ √√ 
 CEX    √√  √ 
 AEX      √ 
 HIC   √√   √ 
FD  Formula 
optimization 
      
‘√’ indicates the quality attribute can be controlled by the corresponding strategy. More 
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‘√√’ means this step is undertakes the major responsibility to control this quality 
attribute. CEX, cation exchange chromatography; AEX, anion exchange 
chromatography, HIC, hydrophobic interaction chromatography 
 
5.5.1. Amino acid sequence 
Amino acid sequence is the primary structure of an mAb. The occurrence of amino 
acid sequence mutation has a huge impact on the mAb efficacy and stability [275, 276], 
thus it should be detected as early as possible. Peptide mapping is an essential technique 
to detect and monitor single amino acid sequence mutation. The principle behind 
peptide mapping is: if two proteins have the same primary structures, then cleavage of 
each protein with a specific protease or chemical cleavage reagent will yield identical 
peptide fragments. However, if the proteins have different primary structures, and the 
cleavage will generate unrelated peptides [277, 278]. 
Though it should be well designed in the new drug discovery stage, the mutation 
may occur during the cell line development stage. It is possible due to the operation of 
gene transfer to the host cells, the impact of the selection pressure or the instability of 
the host cell or the gene itself. If the root cause is because of the gene instability, the 
mAb candidate may need to be turned back to the new drug discovery stage for a better 
molecule design. If the mutation occurs because of the cell engineering operation, either 
changing the selection pressure or rescreening the clones should be taken to solve this 




N-terminal amino acid linked glycosylation is the main type of glycosylation for 
mAbs. The distribution of the modified mAb molecules is named as N-glycan. N-
glycan may impact on the ADCC activity, in-vivo half-time, etc. [268, 279]. One 
straightforward method to control N-glycan is modifying and screening the host cells 
at the cell line development stage. Significant N-glycan difference (> 25 %) has been 
reported among various host cell types [16, 20, 270, 279]. This gap is usually difficult 
to be filled via cell culture. After the host cell line is determined, N-glycan can be 
further regulated during cell culture via medium and process parameter optimization. 
By adding or removing certain chemicals, such as amino acids, manganese ions, 
uracil, and galactose, etc., glycan related metabolic pathways can be directly activated, 
inhibited or changed [268, 280]. Meanwhile, cell culture parameter optimization is a 
mild method to fine-tune the N-glycan. Process parameters, such as temperature, pH, 
and dissolved oxygen etc., can indirectly impact on the intracellular enzymatic activities 
and pathways, and the influence will be reflected by the N-glycan [215, 268, 281]. 
In the industry, cell line and clone screening is the most effective way to 
significantly regulate the N-glycan. Medium and cell culture parameter optimization 
would be the next step to accurately control N-glycan, especially for biosimilar products. 
Matching the glycan profile at early stage is always preferred than doing that in the late 
stages. 
5.5.3. Aggregation 
Protein molecules tend to place the hydrophilic chains into the aqueous solution 
while orientate the hydrophobic chains into a hydrophobic microenvironment [282]. 
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This means proteins may form colloids which is observed as aggregation. Aggregation 
negatively impacts on the drug stability and efficacy.  
To reduce the occurrence of aggregation, dispersants can be added into the 
bioreactor during the cell culture process, which should be controlled at a reasonable 
low level because they are toxic to the cells [282]. During the downstream process, 
hydrophobic interaction chromatography can be applied [283]. Typically, the 
aggregation will be < 1% after this downstream unit operation [264].  
5.5.4. Charge Variants 
Charge variants are one profile indicates the distribution of the charged mAb 
molecules. Variation of charge variants leads to the efficacy instability [284]. Usually, 
high contents of neutral mAb molecules from batch to batch are preferred. Constant 
distribution of change variants are required to maintain the quality consistency.  
Bioflavonols, Trace elements, and vitamins are able to impact the charge variants 
during the formation of biologics. By optimizing their contents in the medium, the 
charge variants can be regulated during the cell culture process [285]. Meanwhile, cell 
culture time, pH, and temperature are also influential parameters [207, 269]. During the 
downstream process development, cation exchange chromatography is the major 
method to control this quality attribute by removing certain abundant charged mAb 
fractions. This is an alternative choice when the charge variants are not able to be well 
controlled by cell culture, because this downstream operation may lead to a significant 




Fragmentation refers to mAb molecules losing part of its structure, which is 
exhibited as low molecular weight. [287] They usually occur during the cell culture. 
[288] Fragment profiles will impact on the stability and in-vivo half-time of the 
biologics. Most of the fragmentation mechanisms can be grouped into two types:  
A). Breaking of the disulfide bond(s). It usually yields to free light chain, heavy 
chain and half-mer. [289, 290] 
B). Breaking of peptide bond(s). Various types of fragments may be observed 
depending on the broken peptide bonds.[291] Typical fractured bonds include Asp-Gly 
[292], Asp-Pro [293], Asp-Asp [294], Gly-Thr [295], Gly-Ser [295], Cys-Cys [296], 
Asn-Ser [297], etc.    
To repair the fragments, the fragment mechanism should be confirmed first. If it is 
because of the breaking of the disulfide bond(s), mild oxidizer should be applied to re-
oxidize the free thiol to disulfide. If it is because of breaking of peptide bond(s), 
solutions may be to add enzymes, adjust pH, etc. However, the fragmentation issue is 
difficult to be solved in reality once it occurs, due to the complexity of the fragment 
profile. The fragments may exhibit similar affinity, molecular size and charge variants 
compared to the intact mAb. There are no Protein A, hydrophobic interaction 
chromatography or ion exchange chromatography that is perfect to remove different 
kinds of fragments. [287, 289, 290, 298] Therefore, it is desired to minimize the 
fragment formation via cell culture and the harvest operation.[299]  
5.5.6. Other Impurities 
Purity is the basic and critical requirement for mAbs. While upstream produces 
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numerous by-products simultaneously with the target mAb, downstream bears the task 
to remove all the impurities.[287] Other than the above discussed CQAs, other 
impurities include host cell proteins (HCP), DNA, leached materials from previous unit 
operations, medium components, endotoxins and virus. [276] Protein A 
chromatography is one of the most important unit operation for highly efficient mAb 
capture and impurities removing. It distinguishes itself with high selectivity on IgG type 
antibodies. [283] During this step, most HCP, DNA, medium components and virus 
particles are removed. [300, 301] The major disadvantage of Protein A is the high cost. 
In the industry, multiple cycles are applied to the Protein A unit operation to improve 
the utilization efficiency.[283, 300] 
Directly after the protein A, ion exchange chromatography is often used to further 
remove the remaining HCP, residual DNA, leached protein A materials, medium 
components, endotoxins and virus.[302, 303] Hydrophobic interaction chromatography 
is then used as a complementary to remove most aggregates. [283]    
 
5.6. Challenges and Trends 
Process development is the bridge to achieve high quality products in 
manufacturing. Challenges exist to meet the increasing demands of high quality 
biologics, including:  
A). Scale-up stability. Though, a couple of scale-up strategies have been built up 
during the recent decade, it is not rare to observe quality attribute variation when the 
process is scaled up to a pilot (250 – 1,000 L) or full (2,000 – 25,000 L) scale production 
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system, especially in the upstream due to the involvement of cells.  
B). Lack of efficient methods to solve some quality problems. In the upstream, a 
single medium component or operation parameter change may impact on multiple 
metabolic pathways. Thus, it is not easy to accurately regulate one single quality 
attribute without influencing others. Meanwhile, downstream has few methods to polish 
N-glycan profile, or recover the fragments to intact mAbs.     
C). New and validated processes to meet the recent perfusion and single-use 
technologies. A perfusion bioreactor operation may last up to three months for 
continuous upstream and downstream production, which requires higher product 
quality stability than the current fed-batch bioreactor operations. Single-use bioreactors 
are good for rapid production and risk control of sterilization. However, leachables and 
extractables from single-use bioreactor construction materials need to be well validated 
before utilization. In the downstream, it is difficult to implement based solely on sing-
use bioreactors due to the high expense of the columns.  
 
5.7. Conclusion 
The demands on high quality biologics will continue to increase in the coming 
decades. Process development takes the responsibility to set up technologies for high 
quality biologics manufacturing. In this chapter, the tasks of different process 
development stages were briefly reviewed. The concept of QbD and process 
development strategies for quality control were summarized. Continuous input is 






Chapter 6  
Summary and Outlook 
Impacted by the continuous progress of medical insurance system, drug 
manufacturing technology and new drug discovery all over the world, much attention 
has been attracted to the biopharmaceutical industry globally. Rapid and accurate 
methods for biologics screening are process development are highly demanded to 
ensure efficient and successful biopharmaceutical research and commercialization.  
Kinetic modeling, as discussed, is a potential method to meet the above 
requirements. It can be applied for biologics and indication screening, process 
development and elucidating of enzyme kinetic properties, which can serve the 
biopharmaceutical development from different aspects. In this dissertation, all of 
following aspects were discussed: 
A) The application of kinetic modeling for biologics and indication screening; 
B) A novel method for rapid temperature shift strategy screening to reach high titer 
via kinetic modeling; 
C) A mechanistic elucidating of the kinetic properties of lactate dehydrogenase. 
This can be used for explanation the enzyme performance and prediction of 
appropriate drug dosage. 




Though kinetic modeling is not mandatory under the current regulation, there’s no 
doubt, well developed models explaining the kinetic data would be a bonus to get the 
IND approval. In the Chinese Pharmacopoeia (2015), kinetic modeling is mandatory 
required to explain and predict the thermal and storage stability. It will not be a surprise 
if this modeling strategy is required for other pre-clinical researches in the near future. 
Limited by the research time, this dissertation may not have covered all the aspects 
of kinetic modeling research in the biopharmaceutical industry. A further study can 
continue based on the following suggestions: 
A) Reducing the time and experiment amount for kinetic modeling calculation with 
the prediction accuracy improved; 
B) Modeling for therapeutic protein quality understanding and control; 
C) Modeling for perfusion cell culture and continuous protein purification process 
for developing the next generation manufacturing technology; 
D) Building up kinetic modeling method for scale-up/-down; 
E) Further application of mechanistic kinetic modeling strategy to elucidate crucial 
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